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Abstract 
Navigating psychotropic treatment use for bipolar disorder (BD) in pregnancy is challenging as it 
is, but it is even more difficult with use of multiple medications across various drug classes for 
treatment, given the absence of evidence of their safe use. This retrospective cohort study 
assessed prescription patterns, patient characteristics associated with these patterns, risk of 
adverse outcomes, and rates of readmission in women with BD who were prescribed 
antipsychotic, antidepressant, or combination treatment during pregnancy, relative to untreated 
women. An estimated 25% of women were prescribed psychotropic drugs during pregnancy. 
Women with past suicide attempts and those with recurrence(s) during pregnancy were more 
likely to be prescribed antipsychotics only, whereas women with a history of alcohol-related 
disorders were less likely. Women with obesity related disorders were less likely to be prescribed 
antidepressants alone in pregnancy. The number of prior psychiatric emergency department visits 
was associated with use of combination antipsychotic and antidepressant therapy. This study 
found no statistically significant association between type of treatments prescribed and perinatal 
and psychiatric outcomes.  
Keywords 
bipolar disorder, pregnancy, adverse outcomes, readmission, treatment, polytherapy,  
combination treatment
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Chapter 1  
1 Overview  
Fluctuations in mood are normal, but for patients diagnosed with bipolar disorder (BD), mood 
disturbances are far more severe, exceed healthy and socially acceptable limits, and may persist 
for extended periods of time. The Diagnostic and Statistical Manual of Mental Disorders, 5th 
edition (DSM-5) characterizes BD by more than one manic or depressive episode separated by 
periods of remission.1 Although there is no cure for BD, treatment is available to manage 
relapses and alleviate mood symptoms. 
BD is a chronic and episodic mental illness requiring long-term treatment, which typically 
involves the use of psychotropic drugs. The number and types of medications for BD treatment 
has expanded substantially over the years. In contrast to the 20th century idea that one drug, 
traditionally lithium, was a sufficient treatment for patients with BD, combination therapy has 
become increasingly common in clinical practice. This may be credited to the introduction of 
new drug agents and the inherent complexity of BD treatment as a result of medical 
comorbidities and poor effectiveness and tolerability of other available agents. Recent evidence 
found that few patients receive a single psychotropic agent for their illness.2 Given the 
complexity of BD and the goal of achieving and maintaining remission, multiclass treatment for 
BD is common. Depending on the symptom profile of the patient, mood stabilizers, 
antipsychotics, antidepressants, and anxiolytics are prescribed either alone or in combination.3  
An early age of onset places women at risk of experiencing BD episodes throughout their 
reproductive years.4 Prior evidence suggests that a substantial proportion of women with BD 
experience recurrence episodes during pregnancy,5 and approximately one-third have a 
recurrence in the postpartum period.6 Management of BD using medications is a challenge for 
women who become pregnant or plan to conceive, as none of the psychotropic medications for 
BD are formally approved for use during pregnancy by national drug safety organizations such 
as Health Canada and the Food and Drug Administration. Due to a relatively small molecular 
size and other properties that determine rates of diffusion, psychotropic medications are known 
to cross the placenta at varying degrees and enter the fetal circulation in measurable quantities.7–
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10 For obvious ethical reasons, there have been no randomized controlled trials on the 
medications’ safety in pregnant women. In the absence of such trials, much of the information 
regarding potential risks associated with BD drugs in humans comes from observational studies. 
However, the bulk of prior studies in the literature examined adverse effects of individual drugs 
(in isolation), even though in clinical practice BD patients are commonly prescribed multiple 
drugs across different drug classes.11 
While studies have focused on complications as a result of use of specific psychotropic 
medications, there are remarkably few data on the clinical profile of pregnant women with BD 
who continue treatment in pregnancy, the impact of being exposed to multiple drug classes 
commonly prescribed to BD patients, and the risk-benefit tradeoffs of medication use in this 
population. As such, the aims of the current study were twofold: (1) to describe the 
sociodemographic and clinical profiles of women with BD in Ontario who use medications 
during pregnancy; and (2) to examine potential effects of the use of psychotropic drugs for BD 
during pregnancy on the risk of perinatal and psychiatric outcomes.  
1.1 Structure of the Thesis and Role of the Student 
This thesis was prepared in accordance with The University of Western Ontario’s School of 
Graduate and Postdoctoral Studies monograph format. A detailed review of the literature, along 
with a critical evaluation of related studies, is presented in chapter two. Chapter three outlines 
the methodological details of this thesis, and chapter four summarizes the main findings. Chapter 
five is the discussion of the findings, overall strengths and limitations, as well as implications for 
clinical practice and suggestions for future research. Additional appendices are provided for the 
literature search strategy (Appendix A) and statement of ethics approval (Appendix B).  
The candidate was responsible for all phases of the project except for the database creation. To 
access the data from Institute for Clinical Evaluative Sciences (ICES), the investigator is 
responsible to submit a dataset creation plan with details regarding the cohort definition, 
inclusion and exclusion criteria, and all study variables of interest – this was prepared by the 
candidate with input from the supervisory committee and other experts at ICES. The de-
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identified dataset was created by ICES analysts and loaded onto a secure online portal to be 
accessed by the candidate for further modifications (i.e. recoding) and analysis. 
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Chapter 2  
2 Literature Review 
This chapter provides an overview of BD, examines the current state of knowledge related to the 
study objectives, and provides background information on all study variables. A comprehensive 
search strategy was conducted using multiple academic databases (details in Appendix A). 
2.1 Bipolar Disorder 
2.1.1 Overview 
Bipolar disorder (BD), previously known as manic-depression, is classified as a mood disorder in 
the DSM-5.1 The DSM is a diagnostic tool for phenomenology-based classification of mental 
disorders. BD includes a spectrum of illnesses characterized by frequent recurrences of mood 
episodes, leading to marked changes in a person’s mood and behavior. It is an episodic illness, 
usually separated by periods of full remission or euthymia between episodes. Mood alterations in 
people with BD range from an elevated, irritable, or euphoric (manic) state to sad, hopeless and 
withdrawn (depressed).1  Among people with BD, mood episodes vary in frequency, duration, 
and symptomatology. Diagnosis of BD requires that a patient experiences both symptomatic 
poles of the illness, with at least one episode of mania in people with bipolar type I,  or 
hypomania (a milder form of mania) and one or more depressive episodes in people with bipolar 
type II disorder.1 The requirement for mania or hypomania to be present at some point during the 
course of the illness distinguishes BD from other mood disorders, namely major depressive 
disorder in which patients suffer from one or more of depressive episodes without ever 
experiencing an episode of mania.1 
2.1.2 Clinical Picture 
Depressive and manic or hypomanic states are two cardinal symptoms of BD. Manic or 
hypomanic episodes are typically characterized by heightened mood, rapid speech, racing 
thoughts, increased physical and mental activity levels, greater energy (with a corresponding 
decreased need for sleep), irritability, perceptual acuity, heightened sexuality, and impulsivity.12 
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In hypomania, the above changes are more moderate, and generally the episode is not severe 
enough to cause impaired functioning.1 In sharp contrast, depressive symptoms are characterized 
by slowing of all aspects of emotion and behavior. This includes the rate of thought and speech, 
energy, sexuality, and ability to experience pleasure.12 Mixed features are present in a patient 
who meets the criteria for both manic and depressive episodes every day for one week. For 
example, a patient may experience excitability of mania coupled with depressed mood. A 
summary of the possible clinical manifestations of BD can be found in Table 2.1. 
Table 2.1 Clinical manifestations of each type of bipolar disorder episode 
Episode 
Classification 
Clinical Manifestations 
Depression Episode of either depressed or sad mood; lack of interest or 
pleasure in doing things one previously enjoyed; changes in 
eating, sleeping, or motor activity; feelings of guilt or 
worthlessness; lack of concentration; and suicidal ideation or 
behaviour.  
Mania Episode of elevated, or irritable mood lasting for at least 1 week 
accompanied by ≥3 symptoms (of 7) for elevated/expansive mood 
or irritable mood, respectively, that includes: grandiosity; 
pressured speech; decreased need for sleep; racing thoughts; 
distractibility; increased goal-directed activity or psychomotor 
agitation; and excessive participation in pleasurable but risky 
activities 
Hypomania Episode of at least 4 days of elevated, expansive, or irritable mood 
accompanied by same symptoms described for mania 
Mixed 
Features 
Symptoms unique to both mania and depression occur 
simultaneously or within a short duration of each other, for at least 
1 week 
 
Diagnostic tests do not yet exist for BD – it is primarily diagnosed according to the clinical 
history and symptoms present at assessment. At clinical assessment, BD is classified into 
subtypes based on the symptomatic profile of each person. Each subtype is characterized by a 
unique combination of manic and/or major depressive episodes; the current criteria are outlined 
in the most recent version of the DSM (DSM-5).1 Bipolar I disorder (BD-I) is characterized by 
the presence of at least one manic episode over a period of one week (or during hospitalization), 
preceded or followed by hypomanic or major depressive episodes. Bipolar II disorder (BD-II) is 
characterized by at least one current or past hypomanic episode, lasting a minimum of four days, 
along with one or more major depressive episodes that must last at least two weeks. Diagnosis of 
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BD-I differs from BD-II by whether the patient has experienced any manic episodes in the past. 
To meet the diagnostic criteria, the mood episode(s) must meet the requisite number of 
symptoms outlined in DSM-5, be present most of the day- nearly every day over the specified 
period of time, and bring about a noticeable change from usual behaviour or functioning. The 
term BD will be used throughout this dissertation in reference to both subtypes of the illness.  
2.1.3 Epidemiology 
Over the last two decades, there has been an almost 50% increase in the prevalence of diagnosed 
cases of BD globally.13 It is considered to be a highly disabling condition, primarily due to an 
early onset and its severity and chronicity across the life span.13 The World Health Organization 
(WHO) has ranked BD among the top ten most disabling illnesses in both developed and non-
developed countries, accounting for 7% of the disability caused by mental illness worldwide.14 
Although the prevalence of BD varies across countries, populations, and the definition of BD 
used,15–18 recent estimates from meta-analyses range from 0.7% to 2.0%.16,19–21 In Canada, the 
lifetime risk of BD is estimated at 2.2%,22 with a prevalence of 0.87% and 0.57% of BD-I and 
BD-II  respectively.23  
2.1.4 Age of Onset 
BD can appear at any age, though it typically manifests in late adolescence or early 
adulthood.24,25 Data from a meta-analysis of age at onset from 15 studies yielded a weighted 
mean of 22.5 years.12 It has been found that up to 60% of people with BD present with first 
symptoms before the age of 21 years,12,26 which continue to recur over the person’s lifetime.  
2.1.5 Sex Differences 
Both males and females are susceptible to developing BD, with nearly equal ratio of illness 
between the sexes.15 However, a number of studies have suggested sex differences in the 
epidemiology, comorbidity patterns, and symptom profile of patients with BD. A recent 
systematic review summarizing evidence from the literature described key differences. The 
majority of the studies report an increased risk of BD-II among women.27 Higher prevalence 
rates of BD-II was subsequently reported by Merikangas and colleagues in a large population-
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based study involving 11 countries.28 Additionally, the review found alcohol-use disorders to be 
a common problem among men with BD, whereas eating disorders and post-traumatic stress 
disorder were more common among women. The likelihood of experiencing mixed episodes and 
rapid cycling of the illness was also found to be significantly greater for women than for men. 
Although this review did not find the number of depressive episodes and time spent in 
depression to differ between the sexes,27 more recent studies do show that women tend to have 
more depressive symptoms and maintain a predominately depressive polarity of illness.29–31  
2.2 Etiology of Bipolar Disorder 
A multifactorial model is currently thought to be involved in the development of BD,32  but the 
precise mechanism underlying its etiology is not yet well understood. Research suggests that BD 
is caused by biological predisposition, in combination with social, environmental, and 
neurological risk factors.  
2.2.1 Neurological Factors 
Early research explains BD to be the result of chemical imbalances in the human brain. It is 
hypothesized that changes in the levels of neurotransmitters such as norepinephrine, dopamine, 
and serotonin are key in the pathophysiology of BD. Current pharmacological treatments 
function to modify levels of these neurotransmitters. Dopamine is a neurotransmitter that is 
widely known to help enhance mood. It is found at higher levels in BD patients in a manic phase 
and lower levels during a depressive phase.33 A deficiency in serotonin levels has been observed 
in depressive and euthymic states, suggesting a lower serotonin receptor activity in BD 
patients.34 BD has also been linked to dysfunction of the hypothalamic-pituitary-adrenal (HPA) 
axis, a pathway in the brain thought to be involved mood regulation.35 
2.2.2 Genetic Factors 
There is particularly strong evidence from studies that suggests BD is a heritable illness with 
genetic underpinnings. Several epidemiological, family, adoption, and twin studies have been 
published in an attempt to disentangle environmental and genetic influences that can predispose 
people to BD.36 One review summarized familial studies and found consistently excess risks 
8 
 
among first-degree relatives of BD patients compared with relatives of non-psychiatrically ill 
groups, 37 particularly among those with early-onset BD.38,39 This suggests that the illness 
aggregates in families and provided some support for the role of genes in the underlying 
etiology. Twin studies help establish the role of genetic heritability, the interplay of genes with 
the environment, and estimate their magnitude of influence.36 Studies have reported higher BD 
concordance among monozygotic twins (who are genetically identical) compared to dizygotic 
twins (who share on average half of the genes), providing very compelling evidence for the BD 
gene hypothesis.40–43 However, the concordance rates of BD among twins was not 100%, 
demonstrating that genes alone are not sufficient to cause illness. Today, the etiology BD is best 
explained by the interaction between genes or complex genetic mechanisms, together with 
environmental non-genetic and stochastic factors.44 
2.2.3 Social and Environmental Factors 
Given that having a relative with BD does not guarantee that one will develop the illness 
suggests that other factors play a role in the onset, course, and expression of BD. This is 
supported by a growing body of evidence that the biological vulnerabilities of BD can remain 
dormant until triggered by environmental stressors.45 Major life stressors have the ability to 
increase the likelihood of a recurrence of mania or depression in people with BD. These life 
changes can be positive or negative, for example the death of a loved one or a job promotion. 
Additionally, social support from significant others has been found to predict a more positive 
course of illness compared to no support.46  
2.3 Bipolar Disorder and Pregnancy 
Though no Canadian data exist for the antenatal prevalence of BD, recently published data from 
the UK found a population prevalence of 0.3% for BD-I and BD-II.47 Pre-existing BD has been 
associated with higher risks of obstetrical complications compared to women with no history of 
mental illness or those who developed BD after the index birth,48 suggesting that having the 
disorder, irrespective of treatment status, may be associated with poor birth outcomes. Jablensky 
and colleagues compared women with BD and women without psychiatric disorder to ascertain 
the incidence of complications that occur during pregnancy and delivery. They found a higher 
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incidence of obstetrical complications in women with BD, which included antepartum 
hemorrhage and placental previa.48 Furthermore, women with BD were more likely to have 
gestational hypertension and to give birth to preterm, low birth weight, and small for gestational 
age babies.49,50 Only one study found no association with gestational diabetes, suggesting no 
difference in rates of gestational diabetes between women with and without BD.49 Though these 
studies highlighted that women with BD are at a higher risk of adverse birth outcomes, they did 
not adjust for treatment status, making it difficult to determine whether it was the illness itself or 
treatment use that lead to the complications.  
2.4 Pharmacological Treatment 
2.4.1 Pharmacological Treatment for Bipolar Disorder 
The primary goal of psychotropic treatment for BD is twofold – acute stabilization and 
maintenance. Acute treatment aims to stabilize symptom exacerbations and allow the return to 
pre-morbid level of psychosocial functioning, whereas the goals of maintenance treatment are 
relapse prevention, reduction of subthreshold symptoms, and to maximize functioning in all 
important life domains.1 A review found that with treatment, 19%-25% of patients with BD will 
experience a recurrence every year, compared to 23%-40% of those on placebo.51 If left 
untreated, patients can experience more than ten episodes of full-fledged mania or depression 
during their lifetime.52 The lifetime recurrence risk of an affective episode is as high as 90% in 
people who reported a single manic episode, and more than half of patients (60%) will 
experience recurrence of BD in the first two years of the illness.53 Moreover, despite continual 
treatment, survival analyses from one study found a five year recurrence risk of 73% in BD 
patients following initial diagnosis.53 As such, long-term or maintenance treatment becomes a 
necessity for most patients. Without treatment, BD episodes can become more frequent and 
severe, interfering with daily life and taking longer to subside.54,55 Untreated patients are also at 
risk of increased morbidity, such as increased rates of suicidal behavior and increased 
employment problems and higher social costs (loss of friends and contacts).56,57 Persistent 
unresolved symptoms and a long duration of untreated symptoms can lead to treatment resistance 
in patients. In BD patients, one study found that patients in the early stage of illness who had less 
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than 5 previous episodes were 40% more likely to respond to treatment compared to those with 
more than 10 prior episodes.58  
Treatment of BD includes psychotropic medications and psychosocial treatments 
(psychotherapy, rehabilitation), though medication is considered to be the cornerstone. 
Psychotropic medication, used for both acute exacerbations and long-term maintenance 
treatment, can be further categorized into primary and adjunct medications. Mood stabilizer 
medications are considered the primary treatment for BD, and help reduce swings in abnormal 
moods and prevent future recurrences. Adjunct medications include drugs classified as 
antidepressants, anxiolytics, and antipsychotics, which are commonly used for the short term to 
treat specific symptoms that may occur in a particular phase of the illness, if the patient is 
unresponsive to the standard treatment, or if there is a need for quick response.59 The list of 
medications in each group is detailed in Appendix C. In Canada, the first-line of treatment for 
acute mania consists of mood stabilizers and several atypical antipsychotic agents, whereas first-
line options for management of bipolar depression include mood stabilizers and atypical 
antipsychotic medications either alone or combined with adjunctive use of antidepressant therapy 
as the second-line option.3  
2.4.2 Mood stabilizer Medications 
Mood stabilizers are not a formally recognized therapeutic drug class.3 As defined by Bauer and 
Mitchener (2004),60 medications referred to as mood stabilizers are those that show evidence of 
short-term efficacy for both poles of BD, where it can be used for treatment and maintenance of 
relief from acute manic or depressive symptoms. To date, lithium is the only drug that has been 
shown to be effective in treating all types of BD episodes. However often drugs from different 
therapeutic classes are prescribed, in place of or in addition to mood stabilizers. One such class is 
anticonvulsants; certain medications are approved for use for BD given its mood stabilizing 
properties. These drugs include carbamazepine, valproate, and lamotrigine. Studies have 
highlighted their efficacy in both acute and maintenance treatment of BD.61,62 Newport and 
colleagues found the risk of recurrence to be 3.3 times lower in lamotrigine-treated patients 
compared to patients who opted to discontinue psychotropic treatment during pregnancy.63 
Evidence from placebo controlled trials support lithium's prophylactic effects on relapses, for 
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which the evidence far exceeds that of other agents. Additionally, there is substantial evidence of 
long-term reduction in suicide risk with the use of lithium.64–67 There are drawbacks to lithium 
therapy which include a narrow therapeutic index, the need for regular monitoring of patient's 
plasma concentrations, and poor tolerability.68 Despite this, lithium remains the gold standard for 
treatment of BD. For the purpose of this thesis, lithium was grouped with anticonvulsants to be 
collectively referred to as mood stabilizers, which is consistent with previous studies.69–72  
2.4.3 Antipsychotic Medications 
Antipsychotics are fast-acting anti-manic agents that also help control psychotic symptoms, such 
as hallucinations or delusions. They are used in BD treatment for both acute and maintenance 
phases of the treatment.3 There are two types, typical and atypical antipsychotics. Typical, or 
first generation antipsychotics (FGA) were first developed in the 1950s, whereas atypical or 
second generation antipsychotics (SGA) were approved for use in the 1990s. Atypical 
antipsychotics are used more frequently because they produce less severe neurological side-
effects compared to typical antipsychotics.73,74 Among BD patients, the efficacy of antipsychotic 
treatment is well established.75–77  
2.4.4 Antidepressant Medications 
There has been a marked increase in antidepressant use over the last 10 years, and recent 
prevalence data suggests an increase of over 8% in North America alone.78 Among BD patients, 
prescription data from the US show that 30% of all treatment regimens include antidepressants.79 
Tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) were first 
introduced in the 1950s and are classified as first generation antidepressants, selective serotonin 
reuptake inhibitors (SSRIs) were introduced in the 1980s as second generation antidepressants, 
and serotonin-noradrenaline reuptake inhibitor (SNRIs) were introduced during the 1990s and 
are referred as third generation antidepressants. Among all antidepressants, SSRIs are commonly 
used for treatment of depression in patients with BD. 
There are numerous studies that have examined the efficacy of antidepressants, although there 
are inconsistencies in the literature. Some studies suggested an improvement in depressive 
symptoms with the use of antidepressants,80 while others do not support their role in BD 
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treatment.81,82 One meta-analysis evaluated the efficacy of up to 16 weeks of antidepressant 
adjunct treatment in adult patients in the depressive phase of BD, and the findings suggested that 
augmentation with antidepressants provided no significant benefits over placebo with respect to 
response and remission rates. 83 Moreover, use of antidepressants for BD treatment has become a 
contentious topic, as emerging evidence suggests that use of antidepressants can induce a switch 
to manic or hypomanic episodes, particularly among females, patients diagnosed with BD-I, and 
patients on tricyclic antidepressants.84,85 The risk of switch reported by Viktorin and colleagues 
did not remain in patients treated with both antidepressants and mood stabilizers.84 Another study 
found that switch rates are reduced if mood stabilizers and antidepressants are used concurrently 
(31.6% compared to 84.2%).81 As a result, international and Canadian guidelines recommend 
conservative and short-term use of antidepressants in BD-I patients, and avoiding monotherapy 
completely for BD depression.3,86 However, the evidence regarding the risks of antidepressant 
monotherapy is still debated in the literature.83,85,87 
2.4.5 Antianxiety Medications 
Epidemiologic studies have established that there is a high prevalence of comorbid anxiety 
disorders and insomnia in BD patients.55,88–90 Comorbid anxiety is also independently associated 
with greater disability and severity of BD.91 Thus, antianxiety medications, or anxiolytics, are 
often prescribed to provide sedative effects. Benzodiazepines are one group of antianxiety 
medications most commonly prescribed in BD treatment, with a five-year prevalence of use 
ranging from 58% to 75% in people with BD.92 Though they are not the core treatment for 
mania, they are adjuncts to mood stabilizers to help provide sedative effects for agitated or 
aggressive behaviour and improve sleep. The safety of prescribing benzodiazepines has been 
debated given that benzodiazepines are controlled substances with addictive and abuse potential. 
Given that substance use disorder is a major comorbidity in BD patients,93 treatment with 
benzodiazepine can result in its misuse.94 Additionally, benzodiazepines have been reported to be 
associated with a higher risk of mood episode recurrence in BD patients.95 In general, 
benzodiazepines are not recommended to be prescribed as monotherapy,96 and clinicians are 
encouraged to prescribe the lowest possible dose for a short period of time.3 
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2.4.6 Multiclass Treatment for Bipolar Disorder 
Few drug trials or observational studies have assessed various combinations of drug regimens for 
BD treatment. One randomized trial compared the time to recurrence between patients on 
quetiapine (atypical antipsychotic) with lithium or divalproex (anticonvulsant) and placebo with 
lithium or divalproex. They found that adding quetiapine to the treatment regimen was associated 
with a statistically significantly longer time to relapse of a mood episode.97 Similarly, another 
trial looked at quetiapine combined with lithium or divalproex to assess efficacy in treating BD 
mania. Combination psychotropic treatment was found to be more effective in treating mania 
compared to monotherapy.98 There are more such trials; however, like the ones described, 
controlled studies have most often examined the effects of particular drugs alone, and the effects 
of concomitant drug use for BD were not addressed. One study examined the addition of 
antidepressants as an adjunct treatment to mood stabilizers.82 The study revealed no evidence 
that treatment with a mood stabilizer and an antidepressant conferred a benefit over treatment 
with mood stabilizer monotherapy. Although this study did not look at the effects of a singular 
drug, it is important to note that the list of medications grouped under the drug classes was not 
comprehensive. The antidepressant category included only two drugs, bupropion or paroxetine, 
while mood stabilizers included lithium, valproate, carbamazepine, or other undisclosed Federal 
Drug Agency (FDA) approved antimanic agents. One cross-sectional study by Gazalle and 
colleagues found a positive association between number of suicide attempts and polypharmacy in 
BD patients, potentially suggesting that the use of multiple medications concurrently may be 
associated with severity of BD illness and suicidality.99 
2.5 Treatment Recommendations for Pregnant Women 
Many women with severe mental illness are also mothers, although less frequently than the 
general population.100 All psychotropic medications can readily pass through the placenta, and 
none have been approved by the drug control agencies for use during pregnancy, as double-blind 
placebo controlled trials have not been conducted in pregnant BD patients. Recurrences occur in 
45% to 50% of all pregnancies,101 and one study found that with treatment, 19%-25% of BD 
patients overall will experience a recurrence every year, compared to 23%-40% of those on 
placebo.51 Lack of control over these episodes may put both the woman and the fetus at risk, 
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especially given that BD episodes are associated with an increased risk of alcohol and substance 
use, poor nutrition, smoking, and suicide.12 Due to the potential for risk to the fetus, women with 
BD who are pregnant may discontinue use of medication. One study found that not only is the 
risk of recurrence twofold among women who discontinue mood stabilizers during pregnancy 
when compared to women who continue treatment, but also that more than 40% of the pregnancy 
period is spent in an episode of BD.102 
Management of BD with treatment during pregnancy is complex for both the physician and 
patient involved and requires an informed decision about what constitutes reasonable risk. There 
are no hard and fast rules for treatment as there are individual variations in risks and benefits of 
medication use. Treatment recommendations depend on a patient’s previous and current mental 
health status.96,103 Ideally, a BD patient would consult with their healthcare providers regarding 
pregnancy and develop a management plan before conception. However, this is complicated 
because many pregnancies among patients with BD are unplanned.104 In Canada, the use of 
psychotropic medications during pregnancy is recommended if necessary, with a preference for 
monotherapy, use of the minimum effective dose, and close monitoring of serum levels and 
adjustments of dosages.96,105 Patients who are mostly asymptomatic and are at low risk of relapse 
can consider tapering mood stabilizer prior to conception. Signs of relapse must be closely 
monitored.  Patients at high risk of relapse are recommended to use mood stabilizers in varying 
doses both during and after pregnancy. The safety profile for most psychotropic drug use in 
pregnancy is not clear, although attempts have been made to quantify the risks.  
2.6 Bipolar Disorder Treatment in Pregnancy and Birth 
Outcomes  
2.6.1 Systematic Search Strategy 
We used a systematic search strategy to identify relevant articles from Medline-Ovid, Embase, 
CINAHL, and PsycINFO (inception to September 2017). We developed a search strategy in 
consultation with a professional librarian and adapted it for use in each database. The purpose of 
the literature search was to identify prior studies that examined adverse maternal, neonatal, 
labour or delivery, and psychiatric outcomes of treatment with psychotropic medications for BD 
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during pregnancy. The search strategy was derived using three main concepts – bipolar disorder, 
pregnancy, and treatment with psychotropic medications – along with their respective keywords 
(Appendix A). All identified studies were imported into Covidence software and underwent 
screening. Studies were included if the full-text was in English and they discussed the impact of 
treatment specifically among women with BD during pregnancy. We excluded qualitative review 
articles and case-studies.  
2.6.2 Mood stabilizers and Anticonvulsants  
There is evidence that some mood stabilizers have teratogenic potential, and the risks have been 
reported in depth in the literature.106–108 Among the mood stabilizers and anticonvulsants, the 
reproductive safety risks are best understood for lithium, valproate (valproic acid or sodium 
valproate), carbamazepine, and lamotrigine. Lithium is considered the gold standard treatment 
for BD given its long track record of efficacy, and it remains the first-choice agent to manage 
mood episodes.96 However, lithium has traditionally been considered to be teratogenic due to a 
strong association between lithium and Ebstein’s anomaly, first reported in the early 1970s.109,110 
Subsequent studies have since provided conflicting data about the degree of risk associated with 
maternal lithium use and found that the previous risk was overestimated. Ebstein’s anomaly is 
rather rare in the general population, recently estimated at 0.18 per 100 infants, but its prevalence 
in babies born to women exposed to lithium in the first trimester was also found to be 
considerably low at 0.60 per 100 live births among infants exposed to lithium,111 suggesting that 
it can be used in pregnancy with caution among women for whom other drugs are ineffective, 
where the drugs with a more favorable risk profile are unsuitable, or when the risk of recurrence 
may overshadow the small risk of Ebstein’s anomaly. More recent evidence has also suggested 
an increased risk of fetal cardiovascular anomalies in lithium-exposed pregnancies compared to 
nonteratogenic exposure.112 
Of particular concern is valproate, an anticonvulsant mood stabilizer that is associated with a 
high rate of congenital malformations among infants exposed in utero in first trimester.106 One 
meta-analyses, including more than 60,000 women on valproate monotherapy, reported an 
overall malformation rate of 17.6%.113 These malformations include neural tube defects, effects 
on cognition and brain volume, craniofacial anomalies, cardiac defects, cleft palate, and 
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hypospadias. Additionally, valproate has been linked to neurodevelopmental disorders, with 
autism being the most frequent diagnosis.114 Similarly, intake of the anticonvulsant mood 
stabilizer carbamazepine in the first trimester has also shown increased risk of fetal anomalies,107 
though at a comparatively lower rate of 2.2-2.3% and with no evidence of intellectual 
impairments.106,107.  
In contrast, Lamotrigine is considered to be a safer alternative to other anticonvulsants given the 
evidence of comparatively lower rates of congenital anomalies. However, there remains some 
uncertainty regarding its safety profile. For example, lamotrigine has been linked to oral cleft 
defects;115 however, aggregate studies and a meta-analyses contradict this association.106,116 
Holmes and Hernandez-Diaz (2012) reviewed the literature on other anticonvulsants, specifically 
topiramate and gabapentin.117 They found that although the number of studies is limited, there is 
evidence that topiramate exposed pregnancies are at risk of teratogenicity.117 Information on 
gabapentin was not sufficient to determine teratogenicity. A more recent prospective study on 
gabapentin by Fujii and colleagues (2013) found no increased risk of malformations, but found 
higher rates of preterm birth, low birth weight, and admission to neonatal intensive care.118 
Literature on the effects of other anticonvulsants in a pregnant BD population is scant. 
2.6.3 Antipsychotics 
There has been a considerable rise in the use of antipsychotics over the years, and they are 
prescribed to approximately 0.2-0.3% of all pregnant women.119 There are two types, typical and 
atypical antipsychotics. The consensus on the use of antipsychotics  is that there is little 
difference in perinatal risks between first generation antipsychotics and second generation 
antipsychotics;120 both have limited teratogenic potential and pose minimal risk with regards to 
major congenital malformations.106,121 However, the risk of adverse outcomes cannot be 
completely ruled out given that FGAs have been associated with increased risk of premature 
delivery and exposure in the third trimester has been linked to transient extrapyramidal 
symptoms and withdrawal symptoms. Even though certain first generation antipsychotics are still 
widely used, second generation antipsychotics are favoured in practice owing to fewer side-
effects. They are also the focus of more recent research on antipsychotics, though they have not 
been extensively studied and data on safety is scarce. Early research comparing exposed women 
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with healthy unexposed women report a moderate increase in risk of adverse maternal and infant 
outcomes.120 However, more recent studies comparing exposed women to those with existing 
psychiatric illness but unexposed to SGAs report few associations between antipsychotics and 
adverse birth outcomes.120 One study, conducted by Vigod and colleagues, used propensity score 
methodology to minimize confounding bias and compare two groups of women who are similar 
with respect to their mental health and medical history, with the main difference being the 
antipsychotic treatment exposure. Their results confirmed that antipsychotic use in pregnancy 
posed a minimal risk of adverse outcomes, as antipsychotic users were not at a substantially 
higher risk of maternal and perinatal outcomes that included gestational diabetes, hypertensive 
disorders of pregnancy, venous thromboembolism, preterm birth, and a birth weight of 3rd or 
97th centile compared to non-users.122 They did, however, report higher rates of hypertensive 
disorders, venous thromboembolism, preterm birth, and neonatal mortality in antipsychotic users 
compared to the general population. As a result, the authors suggest that patients prescribed 
antipsychotics in pregnancy should be carefully monitored. 
2.6.4 Antidepressants 
A majority of the studies that evaluated safety of antidepressants in early pregnancy do not 
indicate an enhanced risk of congenital malformations,123–126 but there remains much variation 
between results reported in the literature.127–132 Studies have also linked antidepressants to other 
adverse outcomes, such as low birth weight and preterm birth in neonates,133–137 but some studies 
did not report this relationship and instead found either a non-statistically significant association 
or a significantly lower risk.126,138 Additionally, one review found that women who used 
antidepressants during pregnancy had an increased risk of gestational hypertension, 
preeclampsia, and delivery complications including placental abruption, premature rupture of 
membranes, need for labor induction or Caesarean section, and postpartum hemorrhage. The 
risks increased when medication was consumed later in pregnancy or throughout pregnancy, and 
was slightly higher for serotonin-noradrenaline reuptake inhibitors and tricyclics when compared 
to SSRIs.139 Recently, antidepressant use in pregnancy has also been linked to the development 
of autism spectrum disorders in children.140–143 However, the results of the observational studies 
have been inconsistent.144,145 Brown et al. conducted a population-based study assessing the risk 
of autism disorder with in utero exposure to antidepressant compared to unexposed children. 
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Two methods of analyses were used to control confounding: multivariable regression-adjusted 
analyses and an inverse-probability-of-treatment weighting. Both the crude and multivariable-
regression analyses showed statistically significant associations, but the inverse-probability-of-
treatment-weighted analyses did not. It is important to note that that the effect estimate was 
borderline (95% CI, 0.997-2.59), which one can argue is too close to conclude there is no 
increased risk. A number of meta-analyses have been conducted in an effort to reconcile the 
findings of various studies and come to consensus.146–150 One review was conducted to reconcile 
disparate findings across several meta-analyses and found that the findings across these studies 
have been mostly consistent, suggesting an increased risk of autism in the offspring from 
antidepressant exposure during pregnancy. The risk decreased after adjusting for confounding 
factors, and for the most part is no longer statistically significant after adjusting for maternal 
mental illness.151  
2.6.5 Antianxiety Medications 
Several studies have reported a statistically significant association between use of 
benzodiazepines and certain pregnancy outcomes. Risk of major congenital malformations tends 
to be low,152–154 however poor neonatal outcomes are evident. Benzodiazepine treatment has 
been recently linked to increased risk of cesarean delivery, low birth weight of baby, and 
increased use of ventilator support for the newborn.155 Prolonged use of benzodiazepines, 
particularly during late pregnancy or during labor, has been associated with neonatal effects and 
withdrawal symptoms including poor suckling, hypotonia (floppy infant syndrome), and 
respiratory distress.106 However, it is important to also consider that the risk of untreated anxiety 
and insomnia in pregnancy can potentially trigger recurrences, and may lead to physiologic 
effects, including reduced level of self-care, worsening mood, and impaired functioning.106 
2.7 Polytherapy During Pregnancy 
2.7.1 Prescription Patterns 
Given the complexity of BD, the use of multiple treatments is very common in clinical practice, 
an approach commonly referred to as "rational polypharmacy".156 In the overall BD population, 
studies examining the drug utilization patterns have found that the rates of prescription for 
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monotherapy and polytherapy are quite similar.79,157 To our knowledge, only one study described 
the prescription patterns of concomitant treatments in BD patients during the period of 
pregnancy.158 In their sample of 197 patients treated during pregnancy, 74 (37.6%) patients were 
using combination therapy, while 85 (43.1%) were on a monotherapy regimen.158 
Antidepressants were most frequently used in this population, either as monotherapy or 
combined with other psychotropic medications.  
2.7.2 Treatment and Pregnancy 
Little is known regarding the combined effects of multiclass polypharmacy among pregnant 
women with BD, although there are studies that have assessed polypharmacy in non-BD 
pregnant populations. One population-based cohort study examined neonatal morbidity as a 
result of use of SSRI antidepressants combined with other drug classes known to act on the 
central nervous system, and whether the combined use imposes a larger harm than their use 
alone.159 They found an increased risk of neonatal morbidity for most drug groups when used 
alone, and a stronger effect on when combined with SSRIs. However, the authors did 
acknowledge that confounding by indication cannot be ruled out.  
Another study investigated pregnancy, delivery, and neonatal outcomes in patients prescribed 
atypical antipsychotic monotherapy and polytherapy with other classes of psychotropic 
medications.160 The findings suggest that polytherapy was associated with a higher risk of 
adverse pregnancy outcomes, compared with monotherapy. The polytherapy group had higher 
use of instrumental deliveries, and a greater proportion of neonates who were large for 
gestational age, born premature, transferred to a neonatal intensive care unit, present with poor 
neonatal adaption signs, and had congenital malformations.160 It is important to consider the 
limitations of this study. Given the small sample size (n=133) of exposed women, the analysis 
was conducted without adjusting for key confounders. Additionally, confounding by indication 
was not addressed.  
Lastly, one Swedish study by Boden and colleagues investigated risk of adverse birth outcomes 
in women who are diagnosed with BD and treated with medication during pregnancy.161 Patients 
were classified as being treated if they were received lithium, antipsychotic drugs (except for 
prochlorperazine, levomepromazine, and melperone), or any of the anticonvulsants 
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carbamazepine, lamotrigine, and valproate. Treated and untreated groups were compared to a 
third group of all women in the population who gave birth with no diagnosis of BD who were not 
prescribed psychotropic treatment. The study concluded that women with BD, irrespective of 
their treatment status, had a higher risk of adverse pregnancy outcomes.161 This is suggesting that 
illness itself was contributing to the increase in risk of adverse outcomes. It is important to note 
that BD patients are often prescribed antidepressants in addition to mood stabilizers and 
antipsychotics. This study failed to control for the confounding effects of antidepressant 
medications, despite the evidence of antidepressants playing a role in adverse birth outcomes. It 
is clear that there still remains much uncertainty about the safety of multiple treatment use during 
pregnancy in patients diagnosed with BD.  
2.8  Knowledge Gap 
It is important to recognize that although published guidelines are available for BD treatments in 
pregnancy, recommendations are primarily based on monotherapy and/or drug-specific studies. 
Though monotherapy is most common, we know that it is not the only type of treatment in 
patients with BD, and in many cases, given that current pharmacological treatment is symptom-
based, polytherapy is common.162 Physicians are advised to make every effort to keep the 
number of medications and dosages to a minimum; however, exposure to medications from more 
than one drug class may be unavoidable in some cases. The use of adjunct medications in BD 
patients is further supported by empirical evidence of superior efficacy from use of certain 
combination therapies compared to monotherapy.77,163–165 Most recently, Broeks and colleagues 
found that in their sample of patients, 50% of women were on a polytherapy regimen during 
pregnancy,158 confirming that polypharmacy is frequent during the pregnancy period. As 
highlighted in this chapter, drug trials of particular psychotropic agents have reported teratogenic 
risks in BD patients, which is why many are not recommended for use in pregnant women. Upon 
review of the literature, we found that controlled studies on the use of combination psychotropic 
medication in pregnancy for BD have been uncommon. Other studies have reported a higher risk 
of adverse pregnancy outcomes as a result of psychotropic treatment use in pregnancy in a non-
BD population. However, it is important to compare treatment effects among women with BD 
given that higher risks of adverse outcomes have also been reported in untreated BD patients. 
Whether the risks are compounded, decrease, or remain unaffected by treatment in pregnancy is 
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still unclear. Therefore, increased attention to the study of combinations of modern BD 
treatments in pregnancy is required to determine the most efficacious and safe combinations. 
2.9 Summary and Rationale  
Pregnancy is a thrilling and joyous occasion for most, but for those suffering from BD, it can be 
a distressing experience. With an age of onset precisely overlapping with the time when most 
women are in their reproductive years, it raises the likelihood of considerable burden of BD 
during pregnancy. For serious mental illnesses such as BD, psychotropic medications are 
essential to allow a person to maintain or revert to normal level of functioning. However, the 
treatment decision-making process can be a ‘minefield’ and is seldom free of risks. The decision 
to use medications during pregnancy raises a number of difficult ethical and medical issues, 
which are made more challenging by the lack of adequate information regarding safety. One 
qualitative study evaluated the real world decision-making process for antipsychotics and mood 
stabilizers during pregnancy – the findings suggest that due to the lack of sound evidence for 
clinicians to base their recommendations on, most women had to rely on their best judgment and 
take a guarded risk with their treatment decisions.166 Others may entirely avoid treatment, and 
untreated symptoms carry substantial risks,167 increasing likelihood of relapse and compromising 
antenatal care. Thus, women with BD are at a disadvantage when managing their pregnancies, as 
they may receive either no pharmacotherapy, or pharmacotherapy that is not entirely evidence-
based. 
Primum non nocere (first, do no harm) is a guiding principle for all physicians, where the 
patient’s well-being is always the primary consideration regardless of the intervention or 
procedure introduced. Rational use of psychotropic drugs entails improving one's quality of life 
and functional status while minimizing adverse effects. Among BD patients, medication 
regimens often involve use of concomitant medications from different therapeutic drug classes, 
which include mood stabilizers, antipsychotics, antidepressants, and anxiolytics. However, as 
described in this chapter, current safety guidelines do not reflect polytherapy treatment use. 
There is insufficient guidance for clinicians to deliver evidence-based advice on multiple 
medication use to expectant mothers with BD, and the clinical guidelines reflect the paucity of 
available literature on the effects of polytherapy for BD. Additionally, evidence has shown that 
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women with BD exhibit higher rates of unplanned pregnancies,168 which can inadvertently 
increase the risks. Given the high risk period and lack of relevant studies, further research is 
needed to understand the safety of medication use in pregnant women with BD.  
2.10 Objectives 
Our initial objective was to examine the impact of mood stabilizer medications, accounting for 
interclass polypharmacy, during pregnancy on adverse birth outcomes among women with BD. 
After obtaining our study cohort, we found that we did not have sufficient numbers to include all 
drug classes as part of our objectives. Therefore, we have focused on the three most frequently 
used combinations of treatments from our dataset – specifically antipsychotics, antidepressants, 
and combined therapy with both antipsychotics and antidepressants.  
Our study objectives were: 
1. To describe the patterns of mood stabilizer, antipsychotic, antidepressant, and anxiolytic 
prescriptions during pregnancy over a period of 12 years (2002-2014) in women aged 13 
to 50 years who are diagnosed with bipolar disorder in Ontario. 
2. To identify the factors associated with use of antipsychotics, antidepressants, and 
antipsychotic-antidepressant polytherapy in pregnant women diagnosed with bipolar 
disorder.  
3. To assess the impact of antipsychotics, antidepressants, and antipsychotic-antidepressant 
polytherapy on the risk of maternal, neonatal, and labour and delivery outcomes in 
women with bipolar disorder.  
4. To assess the impact of antipsychotics, antidepressants, antipsychotic-antidepressant 
polytherapy on psychiatric readmission rates during the early postpartum period in 
women with bipolar disorder.  
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Chapter 3  
3 Methods 
This section outlines the methods applied to our secondary analysis of health administrative data. 
Ethics approval was obtained from the Research Ethics Board (REB) at Western University 
(Appendix B). 
3.1 Study Design and Setting 
We conducted a retrospective cohort study using data from April 2002 to March 2014. We used 
the linked healthcare administrative databases from Ontario housed at ICES. Data on physician 
billings, hospitalizations, and prescription drug use for a subset of the population within the 
province of Ontario were obtained.  
3.2 Data Sources 
ICES is an independent, non-profit research organization that maintains population-level data for 
the purposes of research on healthcare, generated from publicly funded healthcare services 
covered under the Ontario Health Insurance Plan (OHIP). As a prescribed entity under the 
Personal Health Information Protection Act (PHIPA), ICES data is an inventory of secure and 
accessible linked health administrative databases for the entire province of Ontario, Canada 
(population of approximately 13 million). Individual ICES data is de-identified using an 
encrypted common identifier or “code” that is specific to each person in the database and is used 
to link multiple health administrative data to ensure privacy and confidentiality. The databases 
described below were accessed for cohort definition, exposure and outcome ascertainment, and 
covariate specification. Diagnoses in these datasets are recorded using the Canadian Coding 
Standards for the International Statistical Classification of Diseases and Related Health Problems 
(hospital) and physician billing claim codes (OHIP).  
 
Canadian Institute for Health Information (CIHI) Discharge Abstract Database (DAD):  
The CIHI-DAD contains data that is abstracted from hospital records, where each record 
corresponds to a single hospitalization. It includes patient-level data, administrative, and clinical 
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data for hospital discharges (acute and chronic care inpatient, day surgery, and rehabilitation) in 
Ontario. Information captured includes diagnosis, procedure, and treatment information. 
Diagnostic codes are classified using the Canadian version of the International Classification of 
Diseases and Related Health Problems, 10th revision, (ICD-10-CA) and procedure codes are 
assigned using Canadian Classification of Health Interventions codes (CCI). Information from 
this data source has been validated, and with a few exceptions in the type of diagnosis, most 
procedures are found to be complete and reliable, with a high degree of accuracy, sensitivity, and 
an almost perfect specificity.169  
 
Ontario Mental Health Reporting System (OMHRS) database: This database contains 
information on adult inpatient psychiatric admissions to a designated mental health bed in 
Ontario from 2005 onward.  It includes detailed information about mental and physical health, 
social support, and service use. Prior to 2005, this data was captured by CIHI-DAD. Diagnoses 
are assigned using DSM-IV classification system. 
 
MOMBABY database: The MOMBABY database is an ICES-created dataset derived from 
CIHI-DAD that deterministically pairs the inpatient hospital records of delivering mothers with 
their newborns. This database contains information on 98% of all hospital deliveries in Ontario 
and was used to identify the obstetric deliveries in this study.170  Each record represents a 
mother-baby pair and contains additional information including maternal age, newborn birth date 
and gestational age, and indicators for stillbirths and multiple births. The MOMBABY dataset is 
derived and validated for use by ICES. 
 
Ontario Drug Benefit (ODB) database: The ODB database stores records of all dispense 
outpatient medication prescriptions paid for by the provincial government. This database has a 
high level of accuracy (overall error rate of less than 1%).171 Eligibility for drug coverage under 
ODB includes unemployment, disability, high prescription drug costs relative to net household 
income, and recipient of home care services. We limited our sample to people covered by ODB 
and used this database’s prescription drug information to define the exposure status. 
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Ontario’s Registered Persons Database (RPDB): The RPDB of the Ontario Ministry of Health 
and Long-Term Care is a population-based registry that provides information about all people 
who are eligible for health coverage under OHIP. The database maintains information on a 
number of patient demographic characteristics. For our purposes, we used RPDB to obtain data 
on patient age (categorized into 4 groups) and income (categorized into groups based on quintiles 
of average neighbourhood income). 
 
Ontario Health Insurance Plan (OHIP) Database: The OHIP database stores information on all 
claims made by clinicians for insured inpatient and outpatient services provided to the residents 
of Ontario. Most physicians bill their services to the province and submit claims for 
reimbursement. Each record in the database represents a service rendered to a specific person, on 
a specific day. For this study, OHIP claims were used to identify treatment history and outcome 
variables.  
 
The National Ambulatory Care Reporting System (NACRS): This database contains information 
on visits to hospitals and community-based ambulatory care facilities. Encounters captured 
include day surgery, some hospital-based outpatient clinic visits (i.e. dialysis clinic), and 
emergency department visits. 
3.3 Cohort Definition 
Our cohort consisted of women with BD, hospitalized for a singleton obstetrical delivery, with a 
conception date between the fiscal years 2002 and 2014. The conception date defined the date of 
cohort entry. It was derived by subtracting the gestational age at delivery from the baby’s date of 
birth. In the case where the baby’s birth date was missing, the mother’s admission date to the 
hospital was used as delivery date. In the case where the mother’s admission date was missing, 
discharge date was used for delivery date.  
 
WHO considers women between the ages of 15 and 49 as those within reproductive age. To 
minimize the possibility of exclusions during cohort creation, we expanded the age range from 
13 to 50. Canadian data suggest that few women (<0.1%) ages 45 and above give birth.172 
Women were included in our study cohort if they met at least one of the following criteria: (i) an 
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inpatient hospitalization with a primary discharge diagnosis of BD any time prior to the index 
pregnancy; (ii) an outpatient OHIP fee code for a mood disorder plus a prescription of a mood 
stabilizer prior to the index pregnancy (note that the outpatient OHIP fee code (296) without a 
prescription would not have been sufficient to identify BD patients because the fee code is used 
concurrently used for diagnosis of unipolar depression). Additionally, women were included in 
the study cohort if they were continuously covered for ODB throughout their pregnancy, defined 
as having filled any provincially funded drug prescription within six months prior to conception 
and another either during their pregnancy or within six months after delivery.  
 
After identifying data on all records of singleton deliveries between 2002 and 2014, we excluded 
observations with missing or invalid maternal IKN numbers. Additional exclusions included: (1) 
women with gestational weeks less than 20 and more than 45 at delivery; (2) pregnancies with 
multiple overlapping records over the study time period; (3) any data with inconsistencies and 
duplicate records for pregnancy; (4) any woman sharing the newborn's IKN, given that we would 
be unable to differentiate between the two persons; (5) observations with missing birth date for 
the baby and the time period between the mother's admission and discharge date greater than 14 
days (since we were unable to determine the conception date for these women; and (6) women 
who filled a treatment prescription up to 30 days prior to pregnancy and none during the period 
of pregnancy. This was done to ensure that all women who may have been exposed to 
medications close to conception were not misclassified into the non-prescription group, avoiding 
any treatment influence from early exposure.  
3.4 Variable Definitions 
The variables were either directly selected from the ICES databases or were derived using a 
combination of standard classification codes or existing variables from ICES databases. For a 
complete list of study variables, definitions, data sources, and formats, please see Appendix D 
and E.  
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3.4.1 Ascertainment of Exposure 
Exposure status was dependent on whether a woman was using psychotropic treatment during 
the period of pregnancy.  A woman would have been considered to be an exposed case if she was 
using one or more medications across the therapeutic drug classes: mood stabilizers, 
antipsychotics, antidepressants, and anxiolytics. For a complete list of all medications in each 
group, see Appendix C. The unexposed group was comprised of women who were not prescribed 
any BD psychotropic treatment during pregnancy.  
Exposed women were further categorized into medication class groups (all combinations of 
mood stabilizers, antipsychotics, antidepressants, and anxiolytics). Women in any of the 
psychotropic treatment categories required two consecutive filled prescriptions of any one of the 
therapeutic classes, mood stabilizers, antidepressants, antipsychotics, or anxiolytics. The 
different classes of medication were created by individually selecting relevant drugs from the 
ODB formulary and grouping them into their respective classes. Two consecutive prescriptions 
were required to increase the likelihood that the woman was taking the medication for the 
prescribed duration. Prescriptions were considered consecutive if it was filled within 1.5 times 
the number of supply days, prior to or after the prescription. For example, if the first prescription 
during pregnancy was a 30-day supply, there should be another prescription filled within 1.5x30 
days (45 days) before or after the date of the first prescription for it to be deemed consecutive. 
This extra window of time captures those women who may fill their prescription after their last 
day of supply. If patients did not refill a second prescription within the allowed time span after 
their first prescription, then they were considered to have a treatment interruption. Women who 
only had one prescription filled were excluded so they were not classified as unexposed. All 
others who did not fall into the above criteria were classified into the non-exposed comparison 
group. 
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Figure 3.1 Outline of patient time-frame of exposure and outcome 
 
3.4.2 Outcome Variables 
Outcome variables were selected because they are considered to be clinically important 
indicators of maternal and neonatal health and they have been previously studied with regards to 
psychotropic drug use and adverse outcomes in pregnancy.122  
Gestational diabetes: This is a type of diabetes mellitus defined as any degree of glucose 
intolerance, with the onset or first recognition during pregnancy. Diagnosed cases of gestational 
diabetes were identified from an outpatient (OHIP) or inpatient (CIHI-DAD) claim. A study 
examined the validity of ICD-10 codes for gestational diabetes in administrative databases 
relative to glucose thresholds from laboratory data and found a high estimated sensitivity (92%) 
and specificity (97%) when combining outpatient and inpatient datasets.171 
Gestational hypertension: This condition is characterized by high blood pressure without the 
presence of excess protein in the urine. High blood pressure is defined by a systolic blood 
pressure of at least 140 mm Hg and/or a diastolic blood pressure of at least 90 mmHg, present on 
two separate occasions, at minimum six hours apart. Gestational hypertension was identified 
using CIHI-DAD discharge diagnosis codes, which is a validated method with a sensitivity of 
83%.173 
Venous thromboembolism (VTE): This is a potentially lethal disorder that encompasses two 
conditions, deep vein thrombosis and pulmonary embolism. The condition occurs when blood 
clots form, commonly in the deep veins of a leg (deep vein thrombosis) and can travel to the 
lungs (pulmonary embolism).  Inpatient and outpatient diagnostic claims were used to ascertain 
29 
 
VTE. Using inpatient claims has been deemed reasonably accurate, as one study has reported an 
estimated sensitivity of 87% and 78% for deep vein thrombosis and pulmonary embolism, 
respectively.174  
Pre-eclampsia or eclampsia: Pre-eclampsia is a disorder that is similar to gestational 
hypertension, in which it is diagnosed as a result of high blood pressure in patients who may not 
have experienced high blood pressure before. It is marked by significant amounts of protein in 
urine, which is a clinical indicator for abnormal kidney function. Pre-eclampsia can progress into 
eclampsia, which is commonly characterized by the development of seizures. Preeclampsia and 
eclampsia were identified using diagnostic codes, a method that has previously been validated. A 
Canadian study reported a sensitivity of 75% and a specificity of 99% using codes from CIHI-
DAD. 173 
Placental Abruption: This is a condition where the placenta prematurely separates from the 
uterine lining and can lead to complications such as bleeding, or in severe cases, fetal death. 
Inpatient and outpatient diagnostic codes were used to identify cases of placental abruption. To 
our knowledge, this method has not been validated.   
 
Placental Infarction: This condition arises when there is an interruption in the blood flow to a 
part of the placental, leading to cell death. Severe cases may lead to placental insufficiency, 
potentially resulting in fetal death. Inpatient diagnosis codes were used to identify cases of 
placental infarction, though to our knowledge, this method has not been validated.   
Maternal Mortality: This term describes the death of a woman from any cause, during pregnancy 
or within 42 of the delivery. Data on maternal mortality were obtained from the RPDB. 
Transfer to Intensive Care Unit (ICU): Women who were transferred to the medical, surgical, or 
trauma ICU during pregnancy were flagged. Given that most women progress through pregnancy 
without any major adverse events, a transfer to ICU can be an indicator of a pregnancy or 
delivery with major complications. A CIHI-DAD variable was used to identify transfers, which 
has not yet been validated. 
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Stillbirth: Fetal death that occurs at or after 20 weeks of gestation is referred to as stillbirth. 
There is no one cause of stillbirth, which is a result of a number of possible causes that may lead 
to fetal death. These causes can be direct, such as a genetic defect, or it may be an indirect cause 
from a complex chain of events that precede the fetal death. Stillbirth events were identified 
using a variable from MOMBABY.  
Congenital Malformations: These are occurrences of structural or functional anomalies that take 
place in intrauterine life and can be identified prenatally. Outpatient and inpatient diagnostic 
codes were used to identify cases of malformations, which has not been previously validated.  
Preterm birth: This is defined as the birth of a baby at or before 37 weeks of gestational age. 
Problems arise as a result of immature organ systems that are not yet fully developed to support 
life. This variable was derived using baby weight variable in DAD.  
Small for gestational age (SGA): This term refers to fetal growth restriction where a newborn’s 
birth weight is lower than the normal threshold for a given gestational age and sex. Using the 
population-based Canadian reference tables, we classified all babies born with a birth weight 
below the 10th percentile for their gestational age and sex as SGA. This variable was derived 
using maternal gestational week and baby weight variable in DAD. 
Large for gestational age (LGA): This term refers to babies with birth weights that are above the 
normal threshold for a given gestational age and sex. Similar to SGA, using the population-based 
Canadian reference tables, we classified all babies born with a birth weight above the 90th 
percentile for their gestational age and sex as LGA. This variable was derived using maternal 
gestational week and baby weight variable in DAD. 
Neonatal Sepsis: Sepsis refers to the human body’s immune response to attack its organs and 
tissues as a result of presence of harmful bacteria/virus or toxin in the bloodstream. If not 
recognized early and treated in time, sepsis can progress into septic shock and death. For the 
purpose of this study, sepsis was an outcome if observed within 90 days of delivery. Events were 
identified using neonatal and adult codes from CIHI-DAD. A validation study found moderate 
level of accuracy, with a sensitivity of 67%.173 
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Neonatal mortality: This refers to a child’s death occurring within the first 27 days of life. This 
data was obtained from the RPDB. 
Neonatal Infection: This was defined as a diagnosis of an infection, from any cause, within 4 
weeks of delivery. Infections are a result of bacteria, viruses, and fungi, which can be life-
threatening given the infant’s underdeveloped immune system and without adequate control, 
may lead to sepsis and death. We used outpatient CIHI-DAD and inpatient OHIP codes to 
identify the occurrence of infection. Accuracy using this method has not been validated 
previously.   
Neonatal Adaptation Syndrome: This term refers to a set of neurobehavioural symptoms in 
infants born to mothers taking certain drugs during pregnancy, which can include antidepressants 
and benzodiazepines. These symptoms are thought to be a result of withdrawal from fetal 
exposure to the drug after delivery. Symptoms that neonates may manifest include jitteriness, 
feeding problems, respiratory distress, and hypoglycemia.175 The window of time for diagnosis 
of neonatal adaptation syndrome for this study was one-year post delivery. These diagnostic 
codes have not been validated previously.   
Respiratory Distress Syndrome (RDS): This event is diagnosed when a neonate’s lungs are not 
sufficiently developed. Specifically, this occurs when there is not enough surfactant produced by 
the lungs, a liquid that allows the lung’s airways to remain open for oxygen inhalation. Lack of 
surfactant affects lung function and reduces the amount of oxygen inhaled, consequently 
increasing carbon dioxide buildup in the blood, leading to progressive organ dysfunction. RDS 
was captured if diagnosis occurred within one year of delivery. Outpatient diagnostic codes from 
CIHI-DAD were used. A validation study has reported a low accuracy (estimated sensitivity of 
50%) from using codes, however, the sensitivity increases in comparison if restricted to severe 
cases of RDS (96%).173 
Neonatal Seizures: Seizures are classified as sudden, incontrollable neuronal activity in the brain. 
Those that occur during the neonatal period are often indicators of serious damage to the brain. 
Seizure was captured as an outcome in the study if it was diagnosed within one year of delivery.  
Inpatient OHIP and outpatient CIHI-DAD codes were used to identify seizures, which to our 
knowledge, has not been previously validated.  
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Neonatal Intraventricular haemorrhage (IVH): This term refers to bleeding inside or around the 
ventricles of the brain, the place where the cerebral spinal fluid is produced. A buildup of 
pressure from the bleeding can damage nerve cells, leading to brain injury. IVH was included as 
an outcome event if it occurred anytime within one year of delivery. Outpatient CIHI-DAD 
codes were used to ascertain IVH, this has not been previously validated for accuracy.  
Cesarean Delivery: This describes a planned or unplanned surgical procedure where a baby is 
delivered through a through an incision in the abdomen and uterus. Since it is a major surgery, it 
carries a higher risk than a vaginal delivery. In most cases, this delivery is performed when a 
vaginal delivery is high risk for the mother or baby.176 We used CIHI-DAD procedural codes to 
identify caesarean delivery, which has shown to be coded accurately (estimated sensitivity of 
99.8%; estimated specificity of 98.7%).169,173 
Forceps or Ventouse Delivery: Forceps and ventouse are two types of tools that are used to assist 
in delivery of a baby. Forceps is a tong-type surgical instrument and ventouse is a vacuum device 
with gentle suction, both help guide the fetus out the birth canal during delivery. Assisted 
delivery is considered when there is a need for immediate delivery, the fetus does not move 
towards the birth canal for delivery, or the mother is not physically able to progress through the 
delivery. We used CIHI-DAD procedure codes to identify assisted delivery, which have been 
validated for accuracy (estimated sensitivity of 99.8%).169 
Induced Labour: This is the process by which labour is artificially induced with the use of 
pharmacological medications or mechanical means. This takes place when it is considered 
clinically safer for a fetus to be delivered than continue through pregnancy. Induction was 
classified using CIHI-DAD procedural codes, which is found to be completely accurate in 
identification (estimated sensitivity of 100%).169 
Episiotomy or delivery with tear (3rd or 4th degree): An episiotomy is a surgical incision to 
create an opening in the perineum, the area between the vagina and anus, to widen the opening 
and deliver the baby. If no incision is made, a tear can unexpectedly occur during delivery.  
Tears are described in degrees, depending on their size and the affected area. Third and fourth 
degrees are severe tears where lacerations extend to the anal sphincter. We used CIHI-DAD 
diagnostic codes for both outcomes. Though diagnostic codes for episiotomy have not been 
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validated, codes for perineal tear have been shown to be very accurate, with an estimated 
sensitivity of 97% and 94% for 3rd and 4th degree tears respectively.173   
Readmission for Mental Health: Readmission represents the proportion of occurrences of an 
unplanned admission to a hospital for any psychiatric cause within a specific time. Given that 
readmission is most often sought when outpatient or community-based care is not sufficient, it 
can reflect poor transition care or coordination to community care, severity of illness, and 
appropriateness of medication upon discharge. In the current study, it could also be indicative of 
a postpartum recurrence of a mood episode. This study used two time points for psychiatric 
readmission: within 7 days and within 12 weeks.   
3.4.3 Potential Confounding Factors 
The potential confounding factors included in all analyses were based on evidence from the 
literature that they are associated with the outcomes of interest, as well as availability of the 
variable in the ICES databases (Appendix E). Covariates included maternal age, number of 
previous births, neighbourhood-level income, obesity, prior alcohol-related or substance-related 
disorders, history of suicide attempt, number of prior BD hospitalizations, number of prior 
emergency department visits, and recurrence episode in current pregnancy. Maternal age was 
categorized into four groups (13-19, 20-29, 30-39, 40-50), number of previous births into three 
categories (0, 1, 2+), and income into quintile-based categories. All other characteristics were 
binary.  
3.5 Outcomes 
We grouped all outcome indicators into six composite groups: maternal outcomes in pregnancy, 
maternal outcomes postpartum, neonatal outcomes, fetal outcomes, labour and delivery 
outcomes, and psychiatric readmission outcomes. Composite groups are those in which several 
individual outcomes are pooled to produce a single outcome. Because many of the outcome 
measures are rare, this was done to increase the number of events for statistical analysis. Each 
indicator within each composite outcome was selected to be included if it was: (1) classified as a 
clinically important health indicator and a major determinant of perinatal morbidity and 
mortality; (2) accurately measured; and (3) available in the ICES data holdings. Composite 
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groups were created based on the person (fetus/newborn or mother) and the timing of the 
outcome (pregnancy, delivery, postpartum). The use of composite outcomes is in line with 
typical prenatal care, which often aims to prevent multiple complications at a time as opposed to 
a singular outcome.177 Table 3.1 lists all the outcomes for each composite group. Composite 
groups were created as binary variables, where if any one of the included outcomes takes place, 
it grants the composite group a positive event.      
Table 3.1 List of outcomes included within each composite group 
Composite Groups Outcome Indicators 
Neonatal Outcomes Preterm birth, small for gestational age, large for 
gestational age, sepsis, mortality, infection, neonatal 
adaption syndrome, respiratory distress syndrome, 
seizure, intraventricular haemorrhage 
Fetal Outcomes Stillbirth, congenital malformation 
Maternal Outcomes (pregnancy) Venous Thromboembolism, gestational diabetes, 
gestational hypertension, preeclampsia or eclampsia,  
placental abruption, placental infarction 
Maternal Outcomes (post-pregnancy) Transfer to ICU, maternal mortality 
Labour and Delivery Outcomes  Caesarean, forceps/ventouse, induced labour, 
episiotomy or delivery with tear (3rd or 4th degree) 
Psychiatric Readmission  Readmission for mental health reasons ≤ 7 days post-
delivery, readmission for mental health reasons within 1 
to 12 weeks post-delivery 
3.6 Statistical Analyses 
Stata (Version 13) was used for all analyses in this study.178 For women with multiple 
pregnancies over the study period, only the first pregnancy was retained for analysis. Univariate 
analyses were conducted to describe the sample in terms of sociodemographic characteristics, 
pre-morbid conditions, current pregnancy and delivery factors, and health service use. Median 
and interquartile range (IQR) was reported for continuous variables and frequencies and 
proportions for categorical variables. 
Our first objective was to describe the BD prescription patterns during pregnancy. We derived all 
combinations of treatment use in pregnancy between the four therapeutic classes. A graph was 
derived with frequencies for each drug class used during pregnancy across the study period.  
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Our second objective was to identify patient-level factors associated with use of treatment 
regimens for BD in pregnancy. Treatment groups were compared to no treatment in pregnancy. 
We ran unadjusted and adjusted modified Poisson regression models with robust variance 
estimation the log link function to avoid overestimation of the standard error.179 This provides a 
direct estimation of prevalence ratios (PR) for each exposure, comparing the treatment group of 
interest with the no treatment unexposed group. This was repeated for each treatment group. 
Results are presented as PR with 95% confidence intervals (CI). Typically log-binomial 
regression model is the preferred method to approximate prevalence ratios,180 however, the 
model failed to converge, which is a common occurrence in the presence of continuous 
independent variables in the model.181 Poisson regression model with robust variance estimates 
is an alternative option to yield estimates of the prevalence ratio.182 
Our third and fourth objectives were to assess the impact of treatment use on various pregnancy 
outcomes, delivery outcomes, and mental health service use. We ran unadjusted and adjusted 
Poisson regression models with robust error variance, which produced estimates of risk ratio 
(RR).179 The complete list of covariates associated with each outcome and the descriptions of 
their associations is summarized in Appendix F. Each treatment group was compared with the no 
medication group to evaluate the association with each composite outcome. Results are presented 
as risk ratios with 95% CIs. 
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Chapter 4  
4 Results 
This chapter summarizes the study findings, beginning with the descriptive statistics and the 
overall trend of psychotropic medication use during the period of pregnancy between 2002 and 
2014 among women with BD. This is followed by a summary of the relationship between patient 
characteristics and BD medication use, and an analysis of the impact of BD treatment during 
pregnancy on perinatal outcomes.  
4.1 Description of Study Cohort 
A total of 5005 pregnancies met the eligibility criteria for the current study. Of these, repeat 
pregnancies were removed, as well as observations with missing data in any variables of interest 
(<10%).The final dataset for analysis included 3357 unique women. A detailed breakdown of the 
cohort derivation is shown in the study flow chart (Figure 4.1). 
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3662 Observations 
Remove duplicate of study ID (multiple 
pregnancies) keeping only first occurrence (n=1343) 
 
 
 
5005 Observations 
3357 Birth Records 
Total observations with missing data (<10%) 
(n=305): 
Income (n=9) 
Previous Birth (n=9) 
Sex of Baby (n=206) 
Previous Preterm Birth (n=60) 
Gestational Weeks (n=60) 
Baby Weight (n=149) 
 
 
 
 
All birth records from ICES 
database between 2002 and 
2014 (n=1,825,703) Exclusions: 
 Not singleton delivery (n=140,204) 
 Non-Ontario residents (n=2416) 
 Ages <13 or >50 (n=566) 
 Not female according to RPDB (n=59) 
 Gestational weeks <20 or >45 (n=3603) 
 Data inconsistencies (n=11) 
 Duplicate pregnancy records (n=232) 
 Women sharing baby IKN numbers (n=546) 
 Unable to classify conception date (n=108) 
 Did not have BD before conception 
(n=1,666,602) 
 No prescription in ODB in 6 months prior to 
pregnancy to 6 months after delivery 
(n=6351) 
 
 
 
Figure 4.1 Cohort selection study flowchart 
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4.2 Patterns of BD Treatment in Pregnancy 
Among all women diagnosed with BD in Ontario with a conception date between 2002 and 
2014, 25% (n=852) were prescribed psychotropic medication during the period of pregnancy. All 
combinations of the four psychotropic medication classes (mood stabilizers, antidepressants, 
antipsychotics, and anxiolytics) were derived. The frequency of each possible drug combination 
between the four drug classes is presented in Figure 4.2. Among all patients with BD using 
psychotropic medication during pregnancy, 74% (n=633) were prescribed medications from a 
single therapeutic drug class (monotherapy; therapeutic drug classes include mood stabilizers, 
antipsychotics, antidepressants, or anxiolytics), whereas 26% (n=219) were on polytherapy, 
where patients are prescribed two or more classes of psychotropic drugs across the therapeutic 
drug classes. Monotherapies ranked from most to least prescribed during pregnancy in BD 
patients were as follows: antipsychotics, antidepressants, mood stabilizers, and anxiolytics.  
Overall, the three most commonly prescribed medication regimens were antipsychotic 
monotherapy, antidepressant monotherapy, and antipsychotic-antidepressant polytherapy. Given 
the low frequency of other treatment combinations, we made a post-hoc decision to examine 
only the three most common medication combinations for the remaining analyses. These three 
groups also allowed us to examine the effect of antipsychotic and antidepressant monotherapy, as 
well as the combined effects of using at least one agent from the two drug classes at once. 
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Figure 4.2 Frequency graph of all drug combinations prescribed to women in pregnancy 
for bipolar disorder between 2002 and 2014 in Ontario 
 
Abbreviations: AP, Antipsychotics; AD, Antidepressants; MS, Mood Stabilizers; AA, Anxiolytics  
 
4.3 Sample Characteristics 
The sample characteristics by treatment group are presented in Table 4.1. Across the treatment 
groups, the largest proportion of the study sample belonged to the 20-29 year age bracket, 
whereas the group with the lowest proportion was the 40-50 year group. With regards to previous 
births, most of the sample had no previous births and resided in the lowest neighbourhood 
income level (quintile category 1). The frequencies of obesity-related disorders (17%), 
recurrence episodes in pregnancy (30%), and diagnosis of placental previa (4.5%) among 
antipsychotic users were higher than in the other treatment groups. More than half of the 
antidepressant monotherapy sample (56%) were previously diagnosed with substance-related 
disorders, whereas a larger proportion of those on a polytherapy regimen were previously 
diagnosed with alcohol related disorders (32%), gestational diabetes (6%), preeclampsia or 
eclampsia (3%), or had higher rates of previous psychiatric emergency department visits (30%). 
The proportions were nearly identical between the treatment groups for previous diagnosis of 
attempted suicide, hypertension, diabetes, thromboembolic disease, preterm birth, current 
epidural use, and prior psychiatric admission rates.  
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Table 4.1 Baseline characteristics of treatment exposed and non-exposed women in 
pregnancy 
 No Drug Use 
in Pregnancy 
(n=2505)  
Antipsychotic 
Treatment in 
pregnancy 
(n=375) 
Antidepressant 
Treatment in 
Pregnancy 
(n=149) 
Antipsychotic 
and 
Antidepressant 
Polytherapy 
(n=63) 
Demographic  
Age Group n (%) (years)     
13-19 187 (7.5) 28 (7.5) (<5%)a (<5%)a 
20-29 1427 (57.0) 222 (59.2) 80 (53.7) 32 (50.8) 
30-39  815 (32.5) 117 (31.2) 59 (39.6) 29 (46.0) 
40-50 (<5%)a (<5%)a (<5%)a (<5%)a 
Number of Previous Births     
0 1140 (45.5) 185 (49.3) 66 (44.3) 31 (49.2) 
1 702 (28.0) 104 (27.7) 42 (28.2) 16 (25.4) 
2+ 663 (26.5) 86 (22.9) 41 (27.5) 16 (25.4) 
Income category      
1- Lowest neighbourhood income 
category 
1069 (42.7) 183 (48.8) 59 (39.6) 27 (42.9) 
2 593 (23.7) 86 (22.9) 33 (22.2) 11 (17.5) 
3 382 (15.3) 43 (11.5) 27 (18.1) 7 (11.1) 
4 266 (10.6) 38 (10.1) 18 (12.1) 12 (19.1) 
5 (<5%)a 25 (6.7) 12 (8.1) 6 (9.5) 
Comorbid Disorders 
Obesity Related Disorders 339 (13.5) 62 (16.5) 17 (11.4) 7 (11.1) 
Alcohol Related Disorders 580 (23.2) 76 (20.3) 37 (24.8) 20 (31.8) 
Substance Related Disorders 1126 (45.0) 179 (47.7) 83 (55.7) 32 (50.8) 
Attempted Suicide 237 (9.5) 43 (11.5) 15 (10.1) 7 (11.1) 
History of Gestational Diabetes (<5%)a (<5%)a (<5%)a 4 (6.4) 
Pre-existing Hypertension (<5%)a (<5%)a (<5%)a (<5%)a 
Pre-existing Diabetes (<5%)a (<5%)a (<5%)a (<5%)a 
Previous Pregnancy with 
Preeclampsia/Eclampsia 
(<5%)a (<5%)a (<5%)a (<5%)a 
Previous Pregnancy with 
Thromboembolic Disease 
(<5%)a (<5%)a (<5%)a (<5%)a 
Previous Preterm Birth 297 (11.9) 47 (12.5) 20 (13.4) 9 (14.3) 
Current Pregnancy or Delivery 
Recurrence of Mood Episode 495 (19.8) 113 (30.1) 29 (19.5) 17 (27.0) 
Rapid Repeat Pregnancy (<5%)a (<5%)a (<5%)a (<5%)a 
Placental Previa (<5%)a (<5%)a (<5%)a (<5%)a 
Use of Epidural  (<5%)a (<5%)a (<5%)a (<5%)a 
Health Service Use 
Number of BD Hospitalizations Prior 
to Pregnancy, median (IQR) 
(<5%)a (<5%)a (<5%)a (<5%)a 
Psychiatric Emergency Department 
Visits Prior to Pregnancy 
594 (23.7) 106 (28.3) 29 (19.5) 19 (30.2) 
a- ICES does not allow reporting of cell values of less than 6 
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4.4 Composite Outcomes 
Composite outcomes were created using various outcome indicators, and the frequency of each is 
reported in Table 4.2. The most frequent composite outcome among all pregnant women with 
BD was labour and delivery outcomes (56%), followed by neonatal outcomes (42%), maternal 
outcomes in pregnancy (9.0%), fetal outcomes (8.5%), psychiatric readmission outcomes (3.3%), 
and maternal outcomes post-pregnancy (0.4%). The number of observations in the composite 
group maternal outcomes post-pregnancy group was very low (<2%) and was therefore was 
dropped from the analyses.  
Table 4.2 Frequency of events of composite outcomes by treatment combinations 
 Bipolar Disorder Treatment Classes 
No Drug  
(n=2505) 
Antipsychotic 
(n=375) 
Antidepressant 
(n=149) 
Antipsychotic 
and 
Antidepressant 
(n=63) 
Maternal Outcomes 
Pregnancy (n=303) 
238 (9.5%) 40 (10.67%) 13 (8.72%) 12 (19.05%) 
Maternal Outcomes 
Post-Pregnancy (n=15) 
(<5%)a (<5%)a (<5%)a (<5%)a 
Fetal Outcomes (n=287) 224 (8.94%) 38 (10.13%) 18 (12.08%) 7 (11.11%) 
Neonatal Outcomes 
(n=1394) 
1119 (44.67%) 174 (46.40%) 68 (45.64%) 33 (52.38%) 
Labour and Delivery 
Outcomes (n=1867) 
1501 (59.92%) 231 (61.60%) 93 (62.42%) 42 (66.67%) 
Psychiatric Readmission 
(n=109) 
(<5%)a (<5%)a (<5%)a (<10%)a 
a- ICES does not allow reporting of cell values of less than 6 
4.5 Factors Associated with Type of Medication Use 
Our second objective was to determine whether patient characteristics were associated with the 
use of antipsychotic, antidepressant, or antipsychotic and antidepressant polytherapy during 
pregnancy, compared to no medication use. Unadjusted and adjusted prevalence ratio estimates 
from the analysis are presented in Table 4.3-4.5. In the adjusted models, we found an association 
between history of suicide attempts and antipsychotic prescription, whereby patients with suicide 
attempts were 1.45 times (95% CI=1.03-2.04) more likely to be prescribed antipsychotics than 
those using no psychotropic medication during pregnancy. Additionally, patients who 
experienced a recurrence during their pregnancies were 1.58 times (95% CI=1.20-2.10) more 
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likely to be prescribed antipsychotic monotherapy while those with a prior alcohol related 
disorder had a lower prevalence of antipsychotic monotherapy (PR=0.69, 95% CI=0.50-0.94) 
than those who use no medication during pregnancy. Women with a history of obesity-related 
disorders had a lower prevalence of antidepressant monotherapy (PR=0.36, 95% CI=0.15-0.87) 
compared to those using no psychotropic medication in pregnancy. Lastly, with every one-unit 
increase in the number of psychiatric emergency department visits prior to pregnancy, women 
were 1.08 times (95% CI=1.03-1.13) more likely to be prescribed antipsychotic and 
antidepressant polytherapy. 
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Table 4.3 Association between patient characteristics and prescriptions for antipsychotic 
monotherapy in pregnant women with bipolar disorder  
 Antipsychotics (n=375) 
 Unadjusted PR (95% 
CI) 
Adjusted PR (95% 
CI) 
Age Group   
13-19 0.97 (0.67-1.40) 0.95 (0.61-1.49) 
20-29 Reference Reference 
30-39  0.93 (0.76-1.15) 1.00 (0.76-1.32) 
40-50 0.71 (0.36-1.38) 0.42 (0.14-1.30) 
Number of Previous Births   
0 Reference Reference 
1 0.92 (0.74-1.16) 0.97 (0.73-1.30) 
2+ 0.82 (0.65-1.05) 0.86 (0.62-1.20) 
Income    
1- Lowest neighbourhood income category  Reference Reference 
2 0.87 (0.68-1.10) 0.85 (0.63-1.15) 
3 0.69 (0.51-0.95)* 0.61 (0.40-0.94)* 
4 0.86 (0.62-1.19) 0.90 (0.61-1.33) 
5 0.78 (0.52-1.15) 0.75 (0.45-1.25) 
Prior Obesity Related Disorders 1.22 (0.95-1.57) 1.22 (0.88-1.69) 
Prior Alcohol Related Disorders 0.86 (0.68-1.09) 0.69 (0.50-0.94)* 
Prior Substance Related Disorders 1.10 (0.91-1.33) 1.19 (0.92-1.55) 
History of Suicide Attempt 1.20 (0.90-1.61) 1.45 (1.03-2.04)* 
Recurrence of Mood Episode in Current Pregnancy 1.61 (1.32-1.97)* 1.58 (1.20-2.10)* 
Number of BD Hospitalizations Prior to Pregnancy 1.03 (0.99-1.08) 1.00 (0.95-1.06) 
Number of Psychiatric Emergency Department Visits 
Prior to Pregnancy 
1.03 (1.00-1.06)* 1.02 (0.98-1.05) 
* p< 0.05 
CI=confidence interval 
 
 
 
 
 
 
44 
 
Table 4.4 Association between patient characteristics and prescriptions for antidepressant 
monotherapy in pregnant women with bipolar disorder 
 Antidepressants (n=149) 
 Unadjusted PR (95% 
CI) 
Adjusted PR (95% 
CI) 
Age Group   
13-19 0.59 (0.26-1.32) 0.64 (0.26-1.56) 
20-29 Reference Reference 
30-39  1.27 (0.92-1.76) 1.17 (0.75-1.82) 
40-50 0.94 (0.35-2.51) 0.86 (0.27-2.70) 
Number of Previous Births   
0 Reference Reference 
1 1.03 (0.71-1.50) 0.70 (0.42-1.16) 
2+ 1.06 (0.73-1.55) 0.88 (0.52-1.48) 
Income    
1- Lowest neighbourhood income category  Reference Reference 
2 1.01 (0.67-1.52) 1.25 (0.75-2.07) 
3 1.26 (0.81-1.96) 1.90 (1.13-3.19)* 
4 1.21 (0.73-2.02) 0.99 (0.48-2.04) 
5 1.01 (0.61-2.03) 1.27 (0.61-2.68) 
Prior Obesity Related Disorders 0.83 (0.51-1.36) 0.36 (0.15-0.87)* 
Prior Alcohol Related Disorders 1.09 (0.76-1.56) 0.97 (0.61-1.55) 
Prior Substance Related Disorders 1.50 (1.10-2.06)* 1.21 (0.81-1.83) 
History of Suicide Attempt 1.07 (0.64-1.79) 1.05 (0.54-2.02) 
Recurrence of Mood Episode in Current Pregnancy 0.98 (0.66-1.46) 1.34 (0.82-2.20) 
Number of BD Hospitalizations Prior to Pregnancy 1.04 (0.96-1.13) 1.03 (0.94-1.13) 
Number of Psychiatric Emergency Department Visits 
Prior to Pregnancy 
0.96 (0.87-1.06) 0.97 (0.86-1.08) 
* p< 0.05 
CI=confidence interval 
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Table 4. 5 Association between patient characteristics and prescriptions for antipsychotic 
and antidepressant polytherapy in pregnant women with bipolar disorder 
 Antipsychotic and Antidepressant 
Polytherapy (n=63) 
 Unadjusted PR (95% 
CI) 
Adjusted PR (95% 
CI) 
Age Groups    
13-19 0.24 (0.03-1.77) 0.34 (0.05-2.47) 
20-29 Reference Reference 
30-39  1.57 (0.95-2.57) 1.65 (0.88-3.10) 
40-50 0.59 (0.08-4.27) 0.89 (0.12-6.42) 
Number of Previous Births:   
0 Reference Reference 
1 0.84 (0.46-1.53) 0.87 (0.42-1.80) 
2+ 0.89 (0.49-1.62) 0.81 (0.38-1.73) 
Income (quintile)   
1- Lowest neighbourhood income quintile Reference Reference 
2 0.74 (0.37-1.48) 1.13 (0.49-2.57) 
3 0.73 (0.32-1.66) 1.26 (0.48-3.29) 
4 1.75 (0.90-3.41) 2.58 (1.14-5.85)* 
5 1.21 (0.51-2.90) 1.96 (0.72-5.33) 
Prior Obesity Related Disorders 0.80 (0.37-1.75) 0.97 (0.41-2.31) 
Prior Alcohol Related Disorders 1.53 (0.90-2.57) 0.96 (0.47-1.98) 
Prior Substance Related Disorders 1.26 (0.77-2.05) 1.20 (0.64-2.26) 
History of Suicide Attempt 1.19 (0.55-2.58) 1.09 (0.41-2.85) 
Recurrence of Mood Episode in Current Pregnancy 1.48 (0.86-2.57) 0.91 (0.41-2.01) 
Number of BD Hospitalizations Prior to Pregnancy 1.05 (0.98-1.12) 1.01 (0.94-1.09) 
Number of Psychiatric Emergency Department Visits 
Prior to Pregnancy 
1.07 (1.03-1.11)* 1.08 (1.03-1.13)* 
* p< 0.05 
CI=confidence interval 
 
4.6 Treatment Use and Study Outcomes 
The third and fourth objectives involved examining the association between antipsychotic 
monotherapy, antidepressant monotherapy, or antipsychotic and antidepressant polytherapy and 
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pregnancy and psychiatric outcomes (Table 4.6). The results of the multivariable regression 
models suggest that women on antipsychotic and antidepressant polytherapy were almost twice 
as likely (RR=1.73, 95% CI 0.99-3.01) to experience adverse maternal outcomes in pregnancy 
compared to women prescribed no psychotropic medication. There was no statistically 
significant association between the type of treatment and neonatal, fetal, labour and delivery, and 
psychiatric outcomes. A table with all unadjusted and adjusted estimates of the effect of 
treatment group, and the covariates for each composite outcome model, is included in 
Appendices G through K. 
Table 4.6 Association between use of treatment combinations in pregnancy and all study 
outcomes 
 Study Outcomes 
Maternal  
RR (95% CI) 
Neonatal  
RR (95% CI) 
Fetal  
RR (95% CI) 
Labour and 
Delivery  
RR (95% CI) 
Psychiatric 
Readmission 
RR (95% CI) 
Antipsychotic 
Treatment 
1.04  
(0.80-1.35) 
1.03  
(0.92-1.16) 
1.11  
(0.80-1.54) 
1.02  
(0.93-1.11) 
0.79 
 (0.40-1.58) 
Antidepressant 
Treatment 
0.94  
(0.60-1.49) 
1.00  
(0.84-1.20) 
1.33  
(0.85-2.09) 
1.03  
(0.91-1.17) 
1.22 
 (0.53-2.85) 
Antipsychotic and 
Antidepressant 
Polytherapy 
1.73  
(0.99-3.01) 
1.13  
(0.90-1.43) 
1.16  
(0.57-2.37) 
1.08 
 (0.91-1.30) 
1.24 
 (0.39-4.00) 
CI=confidence interval 
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Chapter 5  
5 Discussion 
This chapter discusses the primary findings of this study and the clinical implications. 
Additionally, it presents a detailed account of the strengths and limitations of the study. 
5.1 Introduction 
Although avoiding psychotropic medication in pregnancy may be desirable, it is often not safe to 
do so due to the severity of an underlying mental illness. BD is a mental disorder that often 
requires ongoing treatment, including during pregnancy. Thus, it is extremely important to 
evaluate the safety of commonly used treatments for BD in pregnancy. The primary objective of 
this thesis was to examine the risk of adverse outcomes among women using different 
medication combinations during pregnancy. Specifically, we addressed the potential risks 
associated with the use of antipsychotics, antidepressants, mood stabilizers, and antianxiety 
drugs, which we found to be the most commonly used types of medication in this population. 
The outcomes we assessed included maternal, fetal, neonatal, labour and delivery, and 
psychiatric readmissions. Additionally, we described the patterns of medication use in pregnant 
women diagnosed with BD, and explored characteristics of the women with BD who use 
medication in pregnancy. 
5.2 Interpretation of Study Results 
5.2.1 Psychotropic Treatment Patterns 
We obtained a dataset containing data on ODB-eligible women diagnosed with BD with a record 
of a singleton delivery and a conception date between 2002 and 2014. In the study sample, 25% 
were prescribed at least one psychotropic medication during pregnancy and of those, 74% were 
on a monotherapy regimen whereas 26% were using two or more psychotropic medications. This 
proportion was considerably lower than what has been previously reported – Broeks et al. found 
that 53% of their sample redeemed at least one prescription during pregnancy, the percentage 
increased to 58% after considering women who had dispensed prior to pregnancy and had a 
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supply that lasted past conception date.158 This was a less conservative exposure definition than 
was used in the current study. 
Two studies by Broeks et al. and Boden et al., reported prevalence estimates of mood stabilizer 
treatment use in pregnancy of 37% and 6%, respectively. The discrepancy between the two 
studies is likely due to the difference in the definition used to define mood stabilizers. Boden et 
al., included antipsychotic medications in their definition, while Broeks et al. did not. In this 
study, prevalence of mood stabilizer was estimated at 1.6%, which is comparatively lower than 
what was reported previously. It is important to note that the study by Broeks et al. was based out 
of Denmark where they collect population level data on prescriptions which can be accessed 
from a national drug registry. Among all treated patients, Broeks et al. reported 11% of their 
sample using mood stabilizer monotherapy. In this study, approximately 6% of all treated 
mothers were using mood stabilizers. The low rate in this study may be explained by the general 
knowledge of adverse teratogenic outcomes associated with some mood stabilizers – namely, 
anticonvulsants, such as valproate and carbamazepine. However, this is unlikely to fully explain 
the low rate of use of mood stabilizers, as the mainstay treatment for BD is lithium, which is 
recommended as one of the first-line treatment for mood stabilizing in pregnancy.96,183–185 
Studies on psychotropic drug utilization in the larger population of patients with BD have 
reported a decreasing trend in mood stabilizer prescriptions over time.11,186–188 The reason behind 
this declining use has been lithium’s reputation as being a burden to use, coupled with the 
increase in the availability of other treatment options.189 Patients on lithium often need 
monitoring of serum lithium levels on a regular basis to optimize treatment effectiveness  and 
prevent toxicity, and adequate dosing is especially important for the period of pregnancy.190 
Additionally, lithium is not without side-effects, which is concerning for clinicians and patients. 
Because there are no recommendations for lithium in pregnancy in current guidelines, it is likely 
that clinicians are cautious when prescribing, possibly discontinuing completely during 
pregnancy, which reflect the trends observed in this study.  
Antipsychotics were the most frequently prescribed type of medication in pregnancy in this study 
sample, followed by antidepressants. This is in agreement with Canadian guidelines, as 
antipsychotics are among the first-line options for treatment (along with mood stabilizers). The 
high rate of antipsychotic prescriptions reflect an increasing trend observed in the broader 
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population of women with BD. For example, Hayes et al. examined prescribing practices for 
patients with BD from 1995 to 2009 and found that the frequency of prescription of 
antipsychotics increased dramatically.191 Similar changes have been described in Denmark as 
well. A large, nationwide population-based study examined medications prescribed over the 
period 2000–2011. The authors found that prescribing of antipsychotics increased significantly 
over the study period, and that they were the first option of drugs prescribed by 2011.11 
Antipsychotics are an alternative to mood stabilizers for BD patients who are not responsive to 
the latter,192 and their more favorable side-effect profile also may warrant their use in lieu of 
other drug classes.193 They have also been shown to be the preferred treatment for patients who 
present with manic and mixed episodes or with more severe episodes.194  
We found that 17% of the women taking psychotropic medications were using antidepressant 
monotherapy, also widely prescribed in the broader BD population.195,196 Broeks et al. reported a 
prevalence of 41% using antidepressant monotherapy in a population of pregnant BD women.158 
This high prevalence is a worrisome given that the use of antidepressants without concomitant 
use of another drug is not recommended in practice.3 Antidepressant use in absence of a 
concurrent mood stabilizer has been shown to increase risk of treatment-emergent affective 
switches to mania.84 This is especially problematic if induced during the period of pregnancy, as 
a BD episode can potentially compromise the health of the mother or the fetus. Switching may 
not occur when antidepressants are used in conjunction with a mood stabilizer or an 
antipsychotic agent,96 which explains the antipsychotic and antidepressant polytherapy group 
being the third most prescribed combination of treatment in pregnant BD women in this study. 
The proportion of women using medications from more than one drug class was 26%. This did 
not come as a surprise given that polytherapy has become a common treatment regimen for BD 
patients.11,191 Studies have also shown higher efficacy of some combination therapy compared to 
monotherapy for BD treatment.96 Broeks et al. reported a much higher prevalence of polytherapy 
in their sample of pregnant women. They examined the proportion of people using more than one 
class of treatment for at least 90 days and found that 38% of their sample were using 
combination therapy (as per their definition), and an additional 19% were also using combination 
therapy but for less than 90 days. Taken together, approximately 57% of the sample were on 
combination therapy during pregnancy.  Though the proportion found in this study was 
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considerably lower, we cannot make a direct comparison because their study specifically used a 
90-day overlap as the criterion for polytherapy. A lower proportion reported in this study may be 
a result of the absence of available sources of population-wide prescription data used to ascertain 
treated cases.  
5.2.2 Determinants of Treatment Use 
We assessed the role of selected demographic and clinical factors on the type of medication used 
for BD during pregnancy. The prevalence of a history of suicide attempts among patients 
prescribed antipsychotics in pregnancy was 45% higher than that among those taking no 
psychotropic medication for BD in pregnancy. Atypical antipsychotics are often prescribed to 
patients who present with suicidality. Clozapine in particular has the strongest level of evidence 
for anti-suicidal effects among schizophrenia patients.197–200 This may explain why in this study, 
patients with a history of suicide attempts were more often prescribed antipsychotics in 
pregnancy. Because previous suicide attempts are a predictor of suicidality,201 clinicians may 
potentially be prescribing antipsychotics during pregnancy to reduce suicide risk in the high-risk 
patients, especially considering that pregnancy is a vulnerable period, particularly for women 
with BD. We did not find a statistically significant association between history of suicide 
attempts and prescriptions of antidepressants. This finding corresponds with evidence from the 
literature, as antidepressants have minimal effect in helping prevent suicides.202 In fact, some 
studies have reported an apparent increased risk of suicide associated with antidepressant 
use,203,204 although there is still uncertainty regarding this association.86   
The prevalence of recurrences in pregnancy among patients prescribed antipsychotics was 58% 
higher than that among those taking no psychotropic medication for BD in pregnancy. Given that 
we do not have information on the directionality of this association, it could mean one of two 
things. Recurrences may have been higher as a result of the antipsychotics. One potential 
explanation for this is that antipsychotics were not effective in preventing recurrence episodes in 
pregnancy. One study found a higher risk of relapse from antipsychotic compared to mood 
stabilizer monotherapy,205 suggesting, women should instead be treated with other drugs, most 
notably, mood stabilizers. On the other hand, this association could also mean that having a 
relapse in pregnancy may warrant the use of the antipsychotic medication to help alleviate the 
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symptoms as failure to do so may lead to harm to the mother and/or the fetus. According to 
recent Canadian guidelines, antipsychotics are among the first treatment options that should be 
prescribed, regardless of the type of BD episode.3 Thus, it may come as no surprise that there is a 
higher prevalence of antipsychotic prescriptions in women that experience recurrences. The 
prevalence of prior alcohol related disorders was significantly lower among women prescribed 
antipsychotic alone compared to those using no treatment during pregnancy. Given that patients 
with prior alcohol related disorders may also be at risk of alcohol misuse in pregnancy, clinicians 
may potentially be less likely to prescribe antipsychotics in such patients to avoid risk of adverse 
outcomes or interaction of both agents in the body.  
Among patients who were prescribed an antidepressant only, the prevalence of obesity-related 
disorders in the year prior to pregnancy was 64% lower compared to those who were using no 
treatment.  Similarly, one study found that depressed women using antidepressants were more 
likely to be obese.206 A number of antidepressant medications have been found to be associated 
with weight gain in a non-BD patient population.207–211 Therefore, it is possible that clinicians 
may be cautious about prescribing antidepressant treatment in patients who already have a 
history of obesity due to concerns regarding excess weight gain that may occur as a side-effect 
from use. Moreover, patients may prefer to avoid antidepressants if weight gain is a personal 
concern. This issue was observed in one study where a patient’s body weight was found to be a 
factor that influenced the decision to initiate antidepressant treatment.212  
We found that antipsychotic and antidepressant polytherapy was associated with a greater 
number of psychiatric emergency department visits prior to pregnancy. Bearing in mind that 
there are adverse outcomes associated with certain antipsychotics and antidepressants, women 
who are prescribed polytherapy during pregnancy are likely more severe cases of BD.99 These 
women may require multiple medications to help control symptom exacerbations during 
pregnancy. Thus, it is not unexpected for these women to have a history of psychiatric 
emergency department visits prior to pregnancy.  
5.2.3 Treatment Use in Pregnancy 
We failed to find a statistically significant difference in the frequency of the maternal and fetal 
composite outcomes between the treatment groups. Although the association between the 
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antipsychotic and antidepressant polytherapy group was not significantly associated with adverse 
maternal outcomes (95% CI 0.99-3.01) per se, it is very close to being significant. For all intents 
and purposes, this potentially suggests that these women are likely at a higher risk of adverse 
maternal outcomes, which included venous thromboembolism, gestational diabetes, gestational 
hypertension, preeclampsia or eclampsia, placental abruption, or placental infarction. Future 
studies should replicate these findings to help establish the safety profile of these medications 
during pregnancy. 
5.3 Strengths 
There are several strengths of this study. To our knowledge, this is the first study in Canada to 
examine and describe drug utilization patterns in pregnant women with BD. It is worth noting 
that due to ethical concerns, there is an inherent lack of research on the impact of medication use 
during pregnancy. Observational studies such as this one are an important source of information. 
Moreover, this is the first study to examine adverse outcomes as a result of using multiple 
therapeutic drug classes prescribed for BD in pregnancy. This topic is extremely important, but 
existing guidelines do not provide sufficient information. A wide range of outcomes, some of 
which have not been previously examined but are clinically important, were included in this 
study, making the findings of particular interest to patients, clinicians, and regulatory agencies. 
This study used population-level data, which enabled us to identify a large number of cases at a 
relatively low cost. Also, data on study variables were obtained from administrative databases, 
which enabled us to capture the relevant information without influence of recall bias.  
5.4 Limitations 
There are several very important limitations that need to be taken into consideration when 
interpreting the results. Administrative data have limited availability of sociodemographic 
information. Despite our use of large health administrative databases spanning 12 years, our 
sample size was much lower than anticipated when planning the study, which reduced the 
precision of our estimates and produced relatively underpowered analyses. There are several 
reasons for which we were not able to obtain a large sample from an administrative data source. 
First, the method used to identify bipolar diagnosis in the population was imperfect. Ideally, the 
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use of both inpatient and outpatient diagnoses would best capture all BD cases from the 
population. However, since the outpatient classification code for BD also captures cases of 
unipolar depression, we were limited to using inpatient codes and outpatient plus a mood 
stabilizer prescription. This would have missed all cases of outpatient diagnosis combined with a 
different or no BD medication. Second, the literature shows that diagnosis of BD based on 
clinical assessment is not straightforward. Since most patients seek treatment for depressive 
symptoms, which more often than not is the first symptom that emerges in BD patients as 
opposed to mania, BD is often misdiagnosed as unipolar depression. One study found that among 
1000 patients in whom BD was initially misdiagnosed, it takes on average 5.7 years to reach the 
correct diagnosis from the initial misdiagnosis.213 Similarly, another reported that some patients 
can remain misdiagnosed for on average 7 years.214 Not only is this a possible reason for the low 
number of BD cases obtained in this study, but underdiagnoses may have drastically 
underestimated the number of cases over the study period. Moreover, the study would also have 
not captured women who suffer from sub-threshold BD symptoms and do not access healthcare 
services.  
Due to the relatively small sample size, we decided to group the outcome indicators into 
composite outcomes, which also introduced several limitations. We are not able to pinpoint 
exactly which outcome indicator within the group is affected. Because all the medications were 
grouped into classes, with no information on individual medications, we were unable to assess a 
within-class effect, and each medication may differ with respect to their mechanisms of action 
and side effects. We were also not able to assess polypharmacy within class, in which more than 
one agent from the same class is prescribed. As a result, generalizing the conclusions across 
classes without the consideration for within-class polypharmacy may not be a good 
representation of combination psychotropic treatment use. Most importantly, we assessed 
outcomes during pregnancy without any consideration for medication route of administration 
(oral vs. long acting injectable), dosage, duration, and trimester of medication exposure. All 
these are factors that can potentially influence the outcomes of this study.  
To obtain information on drug prescriptions, we used the ODB database. However, the ODB 
only contains data on a subset of the general population of Ontario, which includes those who 
receive support from a social assistance program (Ontario Disability Support Program and/or 
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Ontario Works) or have high drug cost relative to their household income. In this study, of the 
11,356 pregnancies that met the inclusion criteria, 44% were to mothers who were covered by 
the ODB. People eligible for ODB tend to have greater disability, poorer overall health, and 
lower socioeconomic status compared to people who pay for their medications out of pocket or 
through private insurance. Thus, the trends observed in this study may not be generalizable to the 
broader population of women with BD in Ontario. Nonetheless, it is still very important to 
consider the impact of medication in this population given that these women are likely to be 
more susceptible to adverse outcomes than healthier women. Moreover, there may have been 
women who were in fact eligible under the ODB but did not meet the definition used for ODB 
coverage in this study (having filled any provincially funded drug within six months prior to 
conception and another either during their pregnancy or within six months after delivery) and as 
a result may have been excluded from the sample.  
One important limitation of the present study, which is inherent to all observational drug studies, 
the possibility of confounding by indication. This type of confounding arises among a study 
population of patients with the same illness, when those who are exposed to drugs are inherently 
different in terms of distributions of risk factors for the study outcome from patients who are not 
using the drugs.215 This potentially introduces bias because patients who are in either exposure 
groups would differ in their underlying risk of study outcomes. Additionally, we did not consider 
the role of immortal time bias in the analyses. Women with adverse birth outcomes related to 
mortality (i.e. eclampsia) who may have died prior to delivery would have been excluded given 
that to obtain the study sample, we only considered women who survived to delivery. This is a 
limitation since we may not have captured effect of certain severe outcomes if it differs across 
exposure status. There were also limitations to the definitions of variables used in this study. The 
definition for exposure to medication and the cases of BD patients in the population has been 
used in the literature, but has not been previously validated. Moreover, the exposure data on 
psychotropic prescriptions was potentially not fully accurate such that it only provided 
information on medications dispensed, and no information on whether the patient actually used 
the prescribed regimen. Although we included two consecutive prescription fillings in the 
exposure definition to try to minimize this possibility, there was still room for misclassification 
errors. If a patient did not consume a medication that was recorded as prescribed during 
pregnancy, they may have been incorrectly classified into the exposed group of this study. Errors 
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in classification to the non-exposed group may also have occurred if a patient had not filled a 
prescription in pregnancy, but may still be taking medication because they had the supply.  
Additionally, some of the outcomes of interest were likely under-reported – for example, a 
previous study by Joseph et al. examined the validity of diagnostic codes in CIHI-DAD and 
found that respiratory distress syndrome had an estimated sensitivity of 50.9%. The authors 
noted that when they added procedural codes to create a more “severe respiratory distress” 
variable, agreement between the datasets reached nearly 100%. Although a similar approach was 
an option for this study, it would have resulted in a much more restricted respiratory distress 
syndrome variable, making the outcome rarer and less clinically relevant. Furthermore, 
validation studies have proposed more sensitive approaches to capturing certain outcome data 
from administrative databases, specifically when a second source is added. Alotaibi et al. sought 
to evaluate the accuracy of using ICD diagnostic codes combined with imaging codes for 
identifying venous thromboembolism. They found that using imaging codes concurrently 
resulted in the outcome being more accurately captured when compared to physician diagnosis 
obtained by chart review.216 Similarly, another study found that the addition of venous 
thromboembolism treatment codes along with diagnostic codes improved the estimated positive 
predicted value from 72% to 91%.217 One other study assessed venous thromboembolism using 
emergency department diagnosis and found a moderate positive predicted value.218 Although this 
may not be the best source to rely on for venous thromboembolism, using it concurrently with 
hospital discharge codes may demonstrate higher accuracy.  
Some important covariates identified by the literature review were not included in the analysis, 
as we were restricted to those available in the ICES databases. These variables include poor 
prenatal care, smoking status, and BMI; all which are associated with poor outcomes. 
Additionally, we were only able to capture diagnosed alcohol and substance related disorders 
that came to the attention of healthcare services in Ontario. Despite this limitation, however, in 
this thesis we controlled for a wider and more detailed set of covariates than that considered by 
previous studies in this area of research.  
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5.5 Future Directions 
Future research is needed to better understand the trends in treatment use during pregnancy and 
safety of medication use across drug classes among women with BD. There are still many 
unanswered questions regarding concomitant treatment use during pregnancy. Pharmacokinetic 
studies of multiple psychotropic agent use in pregnant BD patients are essential to determine 
how these medications may contribute to potential maternal and fetal risks. Future population-
based cohort studies should also consider stratifying pregnancy outcomes according to the 
trimester of medication exposure. This is because the risk of most pregnancy outcomes may 
differ based on when during the perinatal period the medication was administered to the mother. 
Exposure in the first trimester is commonly a concern for teratogenicity and fetal anomalies 
given that the fetal organs undergo development in that time period, whereas exposure in the 
second and third trimester is related to fetal growth and development of adverse pregnancy 
outcomes. Moreover, it may be worthwhile to include treatment patterns before and after the 
perinatal period as well. This would allow exploration of treatment modifications as a result of 
pregnancy and delivery in new mothers with BD. Furthermore, while this thesis focused 
primarily on short-term outcomes (within one year of delivery, at a maximum), it would be 
important to determine long-term impact in patients using psychotropic drugs for BD during 
pregnancy. Clinicians may benefit from this knowledge to guide on-going care of mothers and 
their children past the period of gestation.  
5.6 Conclusion 
Awareness of adverse drug events is extremely important in clinical settings for safe prescribing 
practices. Our study findings suggest that a substantial proportion of women are using 
psychotropic medications for BD in pregnancy, most commonly antipsychotic monotherapy, 
antidepressant monotherapy, and antipsychotic-antidepressant polytherapy. It is important to 
recognize that prescribing patterns observed in this study do not match the recommendations of 
the Canadian guidelines. Due to the remaining uncertainty of risks from use of multiple 
psychotropic drug classes during pregnancy, limited recommendations can be made. However, 
results from this study are still of interest, providing a measure of risk in an area of research 
where there is limited evidence and few estimates of risk exist. Of importance is that we found 
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no evidence to suggest harm which is a reassuring finding in support of medication use. Caution 
should be exercised when prescribing treatment to mothers with BD, especially those considered 
high-risk for adverse pregnancy outcomes.  
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Appendix A. Literature review database search strategy  
Concept Medline-Ovid Embase PsycINFO CINAHL Keywords 
Bipolar 
Disorder 
Bipolar Disorder exp bipolar 
disorder/  
  
MAINSUBJECT.
EXACT("Bipolar 
Disorder")  
(MH "Bipolar 
Disorder+")  
Bipolar disorder* OR bipolar 
depression OR mania* OR 
maniac OR manic 
OR hypermani* OR 
hypomani* OR bipolar 
affective disorder OR manic 
depression OR bipolar 
spectrum disorder OR  bipolar 
mood disorder OR manic 
depressive syndrome OR 
manic depressive syndrome  
Pregnancy and 
Pregnancy 
Complications 
pregnancy/ or 
gravidity/ or 
pregnancy 
outcome/ 
Pregnancy/ OR 
exp pregnancy 
OR trimesters/ 
OR exp 
pregnancy, 
multiple/ OR 
pregnant women/ 
MJMAINSUBJE
CT.EXACT("Pre
gnancy") OR 
MAINSUBJECT.
EXACT.EXPLO
DE("Pregnancy 
Outcomes") 
(MH 
"Pregnancy+") OR 
(MH "Pregnancy 
Complications+") 
Pregnant OR pregnancy OR 
pregnancies OR gestation* OR 
pregnant women OR child 
bearing OR childbearing 
Psychotropic 
Treatment and 
Combination 
Treatment 
therapeutics/ or 
drug therapy/ or 
drug 
prescriptions/ or 
polypharmacy/ or 
exp Psychotropic 
Drugs/ 
exp psychotropic 
agent/ or exp 
combination drug 
therapy/or exp 
drug therapy/ or 
monotherapy/ or 
polypharmacy/ 
MJMAINSUBJE
CT.EXACT("Dru
gs") OR 
MJMAINSUBJE
CT.EXACT("Dru
g Therapy") 
(MH "Psychotropic 
Drugs+") 
Psychotropic treatment* OR 
psychotropic medication* OR 
drug treatment* OR drug 
therap* OR combination 
treatment* OR polypharmacy 
OR polytherap* OR 
monotherap* OR drug agent* 
OR drug class* 
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Appendix B. Copy of Western REB approval notice  
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Appendix C. List of included medications by drug classes 
Therapeutic Class Sub-Class Medications 
Mood Stabilizers Lithium Agents Lithium agents 
Anticonvulsants Carbamazepine, Clobazam, Divalproex Sodium, Eslicarbazepine Acetate, 
Ethosuximide, Gabapentin, Lacosamide, Lamotrigine, Levetiracetam, 
Carbonate, Methsuximide, Oxcarbazepine, Perampanel, Phenytoin 
(Diphenylhydantoin), Phenytoin (Diphenylhydantoin) Sodium, Pregabalin, 
Primidone, Topiramate, Valproate Sodium, Valproic Acid, Vigabatrin, 
Antipsychotics Typicals (First Generation) Flupentixol Decanoate, Flupentixol Dihydrochloride, Fluphenazine Hcl, 
Haloperidol, Haloperidol Decanoate, Loxapine Succinate , Pericyazine, 
Perphenazine, Pimozide, Prochlorperazine, Thiothixene, Trifluoperazine, 
Atypicals (Second 
Generation) 
Aripiprazole, Asenapine, Clozapine, Lurasidone Hydrochloride, Olanzapine, 
Paliperidone, Paliperidone Palmitate, Quetiapine, Risperidone, Ziprasidone 
HCL Monohydrate 
Antidepressants Tricyclics Amitriptyline, Bupropion HCL, Citalopram Hydrobromide, Clomipramine 
HCL, Desipramine, Doxepin HCL, Imipramine, Mirtazapine, Moclobemide, 
Nortriptyline, Tranylcypromine Sulfate, Trimipramine 
SSRIs Fluoxetine HCL, Paroxetine HCL, Escitalopram, Sertraline HCL 
SNRIs Duloxetine, Venlafaxine HCL 
MAOIs Phenelzine Sulfate 
Others Trazodone Hydrochloride 
Antianxiety Benzodiazepines Bromazepam, Chlordiazepoxide, Clorazepate Dipotassium, Diazepam, 
Hydroxyzine Hcl, Lorazepam, Oxazepam, 
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Appendix D. All study variables and definitions with description of scale of measurement originally obtained from ICES and 
recoded for analysis 
Variables Variable Definition 
Scale of Measurement Description 
Original Analysis 
Exposure and Baseline Variables 
Mood stabilizer treatment Mood stabilizer filled between the 
conception and delivery date  
 
1. Prescribed mood 
stabilizers 
0.  No mood stabilizers 
 
1. Prescribed mood 
stabilizers 
0.  No mood stabilizers 
 
Total number of mood stabilizer 
prescriptions  
If prescribed mood stabilizers (1), list the 
total number of prescriptions filled during 
the period of pregnancy 
1-# 1-# 
Antipsychotic treatment Antipsychotic filled between the 
conception and delivery date  
1. Prescribed 
antipsychotic 
0. No antipsychotic 
1. Prescribed 
antipsychotic 
0. No antipsychotic 
prescribed 
Total number of antipsychotic 
prescriptions  
If prescribed antipsychotic (1), list the 
total number of prescriptions filled during 
the period of pregnancy 
1-# 1-# 
Antianxiety treatment 
(anxiolytics) 
Antianxiety filled between the conception 
and delivery date  
 
1. Prescribed anxiolytics 
0.  No anxiolytics 
prescribed 
1. Prescribed anxiolytics 
0.  No anxiolytics 
prescribed 
Total number of antianxiety 
prescriptions  
If prescribed antianxiety (1), list the total 
number of prescriptions filled during the 
period of pregnancy 
1-# 1-# 
Antidepressant  treatment Antidepressant filled between the 
conception and delivery date  
 
1. Prescribed 
antidepressants  
0.  No antidepressants 
prescribed 
1. Prescribed 
antidepressants  
0.  No antidepressants 
prescribed 
86 
 
Total number of antidepressant 
prescriptions  
If prescribed antidepressant (1), list the 
total number of prescriptions filled during 
the period of pregnancy 
1-# 1-# 
Source of diagnosis Which method was used to diagnose 
individual with bipolar disorder 
1. DAD or OHMRS 
hospitalizations 
2. Outpatient with 
prescription 
1. DAD or OHMRS 
hospitalizations 
2. Outpatient with 
prescription 
Demographic Variables  
Age  Age at delivery 1. 13-19 
2. 20-29 
3.30-39 
4.40-50 
 
1. 13-19 
2. 20-29 
3.30-39 
4.40-50 
 
Parity  Number of previous live births  1-# 1. 0 
2. 1 
3. 2+ 
Income  Rank individual income levels by level of 
marginalization  
1. least 
marginalized to  
5. most marginalized 
1. least 
marginalized to  
5. most marginalized 
Baby's gender Sex at delivery 1. Male 
2. Female 
1. Male 
2. Female 
Year delivery Year of delivery Any year between 2002-
2014 
Any year between 2002-
2014 
Pre-morbid Conditions   
Obesity Patient diagnosed up to one year prior to 
conception and/or in pregnancy 
1. Diagnosed with 
obesity 
0. No diagnosis of 
obesity 
1. Diagnosed with 
obesity 
0. No diagnosis of 
obesity 
Alcohol related disorders Patient diagnosed with alcohol related 
disorders in the year prior to conception 
1. Diagnosed with 
alcohol related disorders 
0. No diagnosis of 
alcohol related disorders 
1. Diagnosed with 
alcohol related disorders 
0. No diagnosis of 
alcohol related disorders 
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Substance related disorders Patient diagnosed with substance related 
disorders in the year prior to conception 
1. Diagnosed with 
substance related disorder 
0. No diagnosis of 
substance related 
disorders 
1. Diagnosed with 
substance related disorder 
0. No diagnosis of 
substance related 
disorders 
Lifetime anxiety disorder 
(includes anxiety neurosis, 
hysteria, neurasthenia,  
obsessive compulsive neurosis, 
reactive depression) 
Diagnosed any time prior to conception 1. Diagnosed with 
lifetime anxiety disorder 
0. No diagnosis of 
lifetime anxiety disorder 
1. Diagnosed with 
lifetime anxiety disorder 
0. No diagnosis of 
lifetime anxiety disorder 
Attempted suicide  Patient had a record of attempted suicide 
any time before conception 
1. History of suicide 
attempt 
0. No history of suicide 
attempt 
1. History of suicide 
attempt 
0. No history of suicide 
attempt 
History of gestational diabetes Patient diagnosed within five years prior 
to conception 
1. Diagnosed with 
gestational diabetes 
0. No diagnosis of 
gestational diabetes 
Missing: If no previous 
pregnancy 
1. Diagnosed with 
gestational diabetes 
0. No diagnosis of 
gestational diabetes 
Missing: If no previous 
pregnancy 
Pre-existing hypertension Patient diagnosed within five years prior 
to conception 
1. Diagnosed with 
hypertension 
0. No diagnosis of 
hypertension 
1. Diagnosed with 
hypertension 
0. No diagnosis of 
hypertension 
Pre-existing diabetes If patient has pre-existing diabetes 1. Pre-existing diabetes 
0. No pre-existing 
diabetes 
1. Pre-existing diabetes 
0. No pre-existing 
diabetes 
Previous pregnancy with pre-
eclampsia 
Diagnosis within 5 years prior to 
conception 
1. Diagnosed with 
preeclampsia 
0. No diagnosis of 
preeclampsia 
1. Diagnosed with 
preeclampsia 
0. No diagnosis of 
preeclampsia 
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Previous pregnancy with deep 
vein thrombosis and pulmonary 
embolism 
(venous thromboembolism 
disease) 
Diagnosis within 5 years prior to 
conception 
1. Diagnosed with 
venous thromboembolism 
disease  
0. No diagnosis of 
venous thromboembolism 
disease 
1. Diagnosed with 
venous thromboembolism 
disease  
0. No diagnosis of 
venous thromboembolism 
disease 
Previous preterm birth  A previous birth from the same mother 
diagnosed with preterm birth  
1. History of preterm 
birth 
0. No history of preterm 
birth or no previous 
delivery 
1. History of preterm 
birth 
0. No history of preterm 
birth or no previous 
delivery 
Current Pregnancy or Delivery Variables 
Recurrence of a mood episode Diagnosis of bipolar disorder or 
depression during the gestation period  
1. Recurrence episode  
0. No recurrence episode 
1. Recurrence episode  
0. No recurrence episode 
Rapid repeat pregnancy  Conception within 6 months of a previous 
delivery 
1. Rapid repeat 
pregnancy 
0. Rapid repeat 
pregnancy/no recent 
hospitalizations for 
delivery 
1. Rapid repeat 
pregnancy 
0. Rapid repeat 
pregnancy/no recent 
hospitalizations for 
delivery 
Placental Previa Diagnosis during the gestation period  1. Diagnosed with 
placental previa 
0. No diagnosis of 
placental previa 
1. Diagnosed with 
placental previa 
0. No diagnosis of 
placental previa 
Gestational weeks Newborn’s gestational weeks at delivery  00-45 00-45 
Newborn’s weight Newborn’s weight at delivery  050-6000 grams 050-6000 grams 
Epidural  Use of epidural at delivery  1. Epidural used 
0. No epidural used 
1. Epidural used 
0. No epidural used 
Service Use Variables  
Maternal psychiatric hospital 
admission 
Previous record of inpatient psychiatric 
admission 
1. Yes 
0. No 
1. Yes 
0. No 
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Maternal emergency department 
visit 
Number of previous psychiatric 
emergency room visits in the year prior to 
conception 
1-# 1-# 
Number of previous bipolar 
hospitalizations 
If diagnosis of bipolar disorder was with 
hospitalization, total number of 
hospitalizations that occurred prior to 
pregnancy 
1-# 1-# 
Outcome Measures 
Delivery Outcomes 
Cesarean delivery Newborn was delivered by cesarean 
delivery 
1. Cesarean delivery 
0. No cesarean delivery 
1. Cesarean delivery 
0. No cesarean delivery 
Delivery with forceps or 
ventouse 
Newborn delivery was an instrumental 
birth  
1. Instrumental delivery  
0. No instrumental 
delivery 
1. Instrumental delivery  
0. No instrumental 
delivery 
Labour induction Labour was artificially induced 1. Induced delivery  
0. No induced delivery 
1. Induced delivery  
0. No induced delivery 
Episiotomy or delivery with 
severe tear 
Perineal trauma from an episiotomy or 3rd 
or 4th degree tear at delivery 
1. Perineal trauma 
0. No perineal trauma 
1. Perineal trauma 
0. No perineal trauma 
Maternal Outcomes (pregnancy) 
Gestational Diabetes Diagnosis between conception and 
delivery 
1. Diagnosed with 
gestational diabetes 
0. No diagnosis of 
gestational diabetes 
1. Diagnosed with 
gestational diabetes 
0. No diagnosis of 
gestational diabetes 
Gestational Hypertension Diagnosis between conception and 
delivery. Except for women who have pre-
existing diabetes (record in Ontario 
Diabetes Dataset) 
1. Diagnosed with 
gestational hypertension 
0. No diagnosis of 
gestational hypertension 
1. Diagnosed with 
gestational hypertension 
0. No diagnosis of 
gestational hypertension 
Preeclampsia and eclampsia 
(PREE) 
Patient diagnosed between 20 week post-
conception and delivery 
1. Diagnosed with PREE 
0. No diagnosis of PREE 
1. Diagnosed with PREE 
0. No diagnosis of PREE 
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Deep vein thrombosis and 
pulmonary embolism 
(venous thromboembolism 
disease) 
Patient diagnosed with during the 
gestation period 
1. Diagnosed with 
venous thromboembolism 
disease 
0. No diagnosis of 
venous thromboembolism 
disease 
1. Diagnosed with 
venous thromboembolism 
disease 
0. No diagnosis of 
venous thromboembolism 
disease 
Placental Abruption Patient diagnosed during the gestation 
period 
1. Diagnosed with 
placental abruption 
0. No diagnosis of 
placental abruption 
1. Diagnosed with 
placental abruption 
0. No diagnosis of 
placental abruption 
Placental Infarction Patient diagnosed during the gestation 
period 
1. Diagnosed with 
placental infarction 
0. No diagnosis of 
placental infarction 
1. Diagnosed with 
placental infarction 
0. No diagnosis of 
placental infarction 
Maternal Outcomes (post pregnancy) 
Late maternal mortality  Flag if maternal death occurred after 42 
days of delivery but within the year 
1. Maternal mortality 
0. No maternal mortality 
1. Maternal mortality 
0. No maternal mortality 
Transfer to ICU Flag if patient transferred to ICU at 
delivery 
1. Transferred to ICU 
0. No transfer to ICU 
1. Transferred to ICU 
0. No transfer to ICU 
Neonatal Outcomes 
Preterm birth Diagnosed if baby is delivered before 37 
weeks of gestation 
N/A (derived) 1. Preterm birth 
0. No preterm birth 
Small for gestational age (SGA) If newborn’s birthweight is below the 10th 
percentile for their gestational age and sex  
N/A (derived) 1. Diagnosed with SGA 
0. No diagnosis of SGA 
Large for gestational age (LGA) If newborn’s birthweight is above the 90th 
percentile for their gestational age and sex  
N/A (derived) 1. Diagnosed with LGA 
0. No diagnosis of LGA 
Neonatal adaption syndrome Newborn diagnosed up to one year after 
delivery 
1. Diagnosed with 
neonatal adaption 
syndrome 
0. No diagnosis of 
neonatal adaption 
syndrome 
1. Diagnosed with 
neonatal adaption 
syndrome 
0. No diagnosis of 
neonatal adaption 
syndrome 
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Respiratory distress syndrome Newborn diagnosed up to one year after 
delivery 
1. Diagnosed with 
respiratory distress 
syndrome 
0. No diagnosis of 
respiratory distress 
syndrome 
1. Diagnosed with 
respiratory distress 
syndrome 
0. No diagnosis of 
respiratory distress 
syndrome 
Seizure Newborn diagnosed up to one year after 
delivery 
1. Diagnosed with seizure 
0. No diagnosis of seizure 
1. Diagnosed with seizure 
0. No diagnosis of seizure 
Sepsis Newborn diagnosed within 90 days of 
delivery 
1. Diagnosed with sepsis 
0. No diagnosis of sepsis 
1. Diagnosed with sepsis 
0. No diagnosis of sepsis 
Intraventricular Hemorrhage 
(IVH) 
Newborn diagnosed within 90 days of 
delivery 
1. Diagnosed with IVH 
0. No diagnosis of IVH 
1. Diagnosed with IVH 
0. No diagnosis of IVH 
Infection Newborn diagnosed within 4 weeks of 
delivery 
1. Diagnosed with 
infection 
0. No diagnosis of 
infection 
1. Diagnosed with 
infection 
0. No diagnosis of 
infection 
Neonatal Mortality  Flag if neonatal death occurred within 27 
days after delivery 
1. Neonatal mortality 
0. No neonatal mortality  
1. Neonatal mortality 
0. No neonatal mortality 
Fetal Outcomes 
Congenital Malformations Newborn diagnosed with at least one 
anomaly at any point within one year after 
delivery 
1. Diagnosis of 
congenital malformation 
0. No diagnosis 
congenital malformations 
1. Diagnosis of 
congenital malformation 
0. No diagnosis 
congenital malformations 
Stillbirth Flag if fetal death occurred after 20 
gestational weeks 
1. Still birth 
0. No still birth 
1. Still birth 
0. No still birth 
Service Use Outcomes 
Readmission (mental health) ≤ 7 
days 
Flag if patient readmitted for mental 
health related concerns within 7 days of 
discharge date after delivery 
1. Patient readmitted 
0. Patient not readmitted 
1. Patient readmitted 
0. Patient not readmitted 
Readmission (mental health) 1 to 
12 weeks 
Flag if patient readmitted for mental 
health related concerns within 12 weeks of 
discharge date after delivery 
1. Patient readmitted 
0. Patient not readmitted 
1. Patient readmitted 
0. Patient not readmitted 
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Appendix E. All study variables and their classification codes used to identify event in health administrative databases with 
description of potential issues with measurement 
Variables 
 
Classification Codes  Potential Issues with Measurement 
Cohort 
Bipolar Disorder Diagnosis 1. A discharge diagnosis of bipolar disorder in the Ontario 
Mental Health Reporting System (OMHRS) 
 
OMHRS codes: 29600, 29601, 29602, 29603, 29604, 29605, 
29606, 29640, 29641, 29642, 29643, 29644, 29645, 29646, 
29650, 29651, 29652, 29653, 29654, 29655, 29656, 29660, 
29661, 29662, 29663, 29664, 29665, 29666, 29670, 29680, 
29689 
2. A diagnosis of bipolar disorder in the Discharge Abstracts 
Database (CIHI-DAD) 
 
DAD ICD-9: 2960, 2961, 2964, 2965, 2966, 2967, 2968 
DAD ICD-10: F300, F301, F302, F308, F309, F310, F311, 
F312, F313, F314, F315, F316, F317, F318, F319  
 
3. OHIP outpatient diagnoses of a mood disorder and at least 
one prescription of a mood stabilizer medication that must 
occur after the OHIP diagnosis  
 
OHIP fee code 296, all non-lab services where location is 
office, phone, long-term care, or home and diagnosis can be 
made by any physician type. 
Missing the subset of the population 
who are diagnosed in outpatient 
clinician settings without a 
prescription 
Baseline Variables 
Pre-morbid Conditions  
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Obesity ICD 10 E66 or ICD 9 278.00-278.02 or 2 OHIP 278 Obesity likely not adequately 
captured because BMI is not 
recorded in database. This variable 
only captured obesity that is formally 
diagnosed 
Alcohol related disorders ICD 10 F10 or ICD 9 291, 303 or  1 OHIP 303 or OMHRS 
30390 
Alcohol use likely not adequately 
captured because alcohol intake is 
not recorded in database. This 
variable only captures alcohol related 
disorders 
Substance related disorders ICD 10 F11-F19 or ICD 9 304, 305 or 1 OHIP 304, 305 or 
OMHRS  30400, 30410, 30420, 30430,30440, 30450, 30460, 
30480, 30490,30510 
Substance use likely not adequately 
captured because substance abuse is 
not recorded in database. This 
variable only captures substance 
related disorders 
Lifetime anxiety disorder 
(includes anxiety neurosis, 
hysteria, neurasthenia,  
obsessive compulsive 
neurosis, reactive 
depression) 
ICD 10 F41 F42 F48.0 or ICD 9 300.00-300.03, 300.09, 300.3, 
300.5 or 2 OHIP 300 or OMHRS 30000, 30001, 30002, 30030 
 
Attempted suicide  ICD 10 X60-X84 or ICD 9 E950-E954 This will not capture attempts that 
are not formally recorded   
History of gestational 
diabetes 
ICD 10-CA E10, E11, E13, E14, 024.8 or ICD 9-CM 648.8 or 
1 OHIP 250 
 
Previous pregnancy with 
pre-eclampsia 
ICD 10-CA O14 or ICD 9-CM 642.40-642.43, 642.50-642.53   
Previous pregnancy with 
deep vein thrombosis and 
pulmonary embolism 
(venous thromboembolism 
disease) 
ICD 10-CA 022.3, O88.2, I80, I26 or ICD 9-CM 671.30-
671.33, 673.20-673.23, 415.1, 451 or 1 OHIP 451, 415 
 
History of renal disease ICD 10-CA I12 or ICD 9-CM 403.0 or 2 OHIP 403  
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Antiphospholipid syndrome 
(AP) 
ICD 10-CA D68.6  or ICD 9-CM 289.81  
Current Pregnancy or Delivery Variables 
Recurrence of a mood 
episode 
1 OHIP 296 or  
 
1. A discharge diagnosis of bipolar disorder in the Ontario 
Mental Health Reporting System (OMHRS) 
 
OMHRS codes: 29600, 29601, 29602, 29603, 29604, 29605, 
29606, 29640, 29641, 29642, 29643, 29644, 29645, 29646, 
29650, 29651, 29652, 29653, 29654, 29655, 29656, 29660, 
29661, 29662, 29663, 29664, 29665, 29666, 29670, 29680, 
29689 
 
2. A diagnosis of bipolar disorder in the Discharge Abstracts 
Database (CIHI-DAD) 
 
DAD ICD-9: 2960, 2961, 2964, 2965, 2966, 2967, 2968 
DAD ICD-10: F300, F301, F302, F308, F309, F310, F311, 
F312, F313, F314, F315, F316, F317, F318, F319  
Will not capture recurrences that are 
not reported  
Placental Previa ICD 10-CA O44 or ICD 9-CM 641.00-641.03 or 1 OHIP 641  
Epidural  CIHI-DAD: CCI 5.LD.20.HA-P1 or CIHI-DAD: CCP 16.91  
Service Use Variables  
Maternal psychiatric 
hospital admission 
ICD 10 F00-F99, G30, G31, R54 or ICD 9 290-319  
Maternal emergency 
department visit 
NACRS DX10CODE: ICD 10 F00-F99, G30, G31, R54  
Number of previous bipolar 
hospitalizations 
1. A discharge diagnosis of bipolar disorder in the Ontario 
Mental Health Reporting System (OMHRS) 
 
OMHRS codes: 29600, 29601, 29602, 29603, 29604, 29605, 
29606, 29640, 29641, 29642, 29643, 29644, 29645, 29646, 
29650, 29651, 29652, 29653, 29654, 29655, 29656, 29660, 
 
95 
 
29661, 29662, 29663, 29664, 29665, 29666, 29670, 29680, 
29689 
2. A diagnosis of bipolar disorder in the Discharge Abstracts 
Database (CIHI-DAD) 
 
DAD ICD-9: 2960, 2961, 2964, 2965, 2966, 2967, 2968 
DAD ICD-10: F300, F301, F302, F308, F309, F310, F311, 
F312, F313, F314, F315, F316, F317, F318, F319  
Outcome Measures 
Delivery Outcomes 
Cesarean delivery CIHI-DAD: CCI 5.MD.60 or  CIHI-DAD: CCP 86.0 to 86.2, 
86.8 or 86.9 
Does not distinguish between 
elective and medically necessary 
procedure 
Delivery with forceps or 
ventouse 
CIHI-DAD: CCI 5.MD.53,54,55, 5MD56PC/PF/PJ or CIHI-
DAD: CCP 84.0, 84.1, 84.2, 84.3, 84.7 
 
Labour induction CIHI-DAD: CCI 5.AC.30 or CIHI-DAD: CCP 85.5 Will capture labour inductions that 
were purposeful due to patient 
preferences 
Episiotomy or delivery with 
severe tear 
CIHI-DAD: CCI 5.MD.50.GH, 5.MD.53.KS/JE/KL/KN/KJ, 
5.MD.54.KJ/KL/KN/NF, 5.MD.55.KN/KL/KJ/KR, 
5MD56PA/PB/PC/PD/PE/PF/PG/PH/PJ, 5PC80JN, 5PD13SB 
or CIHI-DAD: CCP 85.7 
 
Maternal Outcomes (pregnancy) 
Gestational Diabetes ICD 10-CA E10, E11, E13, E14, 024 or ICD 9-CM 648.8 or 1 
OHIP 250 
 
Gestational Hypertension ICD 10-CA O13, I10, I15 or ICD 9-CM642.30-642.33, 642.90-
642.93 
Except when woman is present in the ICES HYPER database 
 
Preeclampsia and eclampsia ICD 10-CA O14, O15 or ICD 9-CM 642.40-642.43, 642.50-
642.53, 642.60-642.63 
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Deep vein thrombosis and 
pulmonary embolism 
(venous thromboembolism 
disease) 
ICD 10-CA 022.3, O88.2, I80, I26 or ICD 9-CM 671.30-
671.33, 673.20-673.23, 415.1, 451 or 1 OHIP 451, 415 
 
Placental Abruption ICD 10-CA O45 or ICD 9-CM 641.20-641.23 or 1 OHIP 641  
Placental Infarction ICD 10-CA O43.81 or ICD 9-CM656.80-656.83  
Maternal Outcomes (post pregnancy) 
Transfer to ICU DAD variable "SCU". Includes values: 
10 = Medical Intensive Care Nursing Unit 
20 = Surgical Intensive Care Nursing Unit 
25 = Trauma Intensive Care Nursing Unit 
30 = Combined Medical/Surgical Intensive Care Nursing Unit 
Not able to capture reason for the 
ICU admission; can unrelated to 
exposure of interest  
Neonatal Outcomes 
Neonatal adaption syndrome ICD 10-CA P96.1 or ICD 9-CM 779.5  
Respiratory distress 
syndrome 
ICD 10-CA P22.0 or ICD 9-CM 769  
Seizure ICD 10-CA P90 or ICD 9-CM 779.0 or 1 OHIP 780  
Sepsis ICD 10-CA P36,A40, A41 or ICD 9-CM 771, 038.0, 038.2,                                                                                                                                                                                         
038.2, 038.1, 038.4, 038.3, 038.8, 038.9 
Intraventricular Hemorrhage ICD 10-CA I61.5, P10.2, P52 or ICD 9-CM 431, 772.0-772.2  
Infection ICD 10-CA P23, P35, P37 or ICD 9-CM 770.0, 771 or 1 OHIP 
486,056,054,070,052,079,010,011,012,015,017,130,112 
 
Fetal Outcomes 
Congenital Malformations ICD 10-CA Q.00-Q.89 or ICD 9-CM 740-757, 759 or 1 OHIP 
743,744,746.748,750,755,759 
 
Psychiatric Readmission Outcome 
Readmission (mental health) 
≤ 7 days 
The most responsible diagnosis of: 
CIHI-DAD ICD 10 F00.X-F99.X, G30.X, G31.X, R54.X or 
ICD 9 290-319 
 
Readmission (mental health) 
1 to 12 weeks 
The most responsible diagnosis of: 
CIHI-DAD ICD 10 F00.X-F99.X, G30.X, G31.X, R54.X or 
ICD 9 290-319 
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Appendix F. Evidence of association between study covariates and composite outcomes 
Composite 
Outcome 
Description of Covariate Association 
Neonatal 
Outcomes 
Age 
 Increased risk of preterm birth219 
 Maternal age of 30-40 increases risk of large for gestational age babies220 
 Maternal age at pregnancy is a risk factor for the development of respiratory distress syndrome in neonates221 
 Risk of neonatal seizures increases with age222,223 
Parity 
 First time pregnancy increases the risk of a preterm birth224  
 Two or more births associated with higher risk of large for gestational age babies220 
 First pregnancy or higher order births are associated with higher risk of maternal mortality225 
 Increases risk of sepsis is neonate226 
 Neonates of women with no previous birth and with 5 or more previous births are at risk of neonatal seizures222 
History of a preterm birth 
 Increases risk of a future preterm birth224 
Placental Previa 
 Increases risk of preterm birth227 
Close conception 
 Conception less than 6 months after a live birth increases risk of a preterm birth and newborn being small for 
gestational age 228,229 
Income 
 Low income increases risks of neonatal mortality230 
Substance Use 
 Misuse of drugs is associated with higher risk of neonatal adaption syndrome231 
Obesity 
 Maternal obesity is associated with higher risk of neonatal seizures222 
Diabetes 
 Maternal diabetes diagnosis is associated with increased risk of neonatal seizures222 
Fetal Outcomes Age 
 Pregnancy in women of advanced maternal age (>35) are at increased risk of stillbirths232 
Parity 
 First birth and 3 or more previous births are both associated with a higher risk of stillbirths233 
Income 
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 Low socioeconomic status is associated with increased risks of birth defecnts234 
Substance abuse 
 Illicit drug use increases risk of stillbirth pregnancies235 
Obesity 
 Increases risk of a stillbirth232,233 
 Risk of congenital anomalies increases in obese pregnant patients236 
Diabetes 
 Increases risk of congenital anomalies in newborn236 
 Pre-existing diabetes has been associated with an increased risk of stillbirths233 
Alcohol 
 Use in pregnancy increases risk of congenital anomalies236 
Maternal 
Outcomes 
(pregnancy) 
Age 
 Pregnancy in women of increasing age is associated with risk of gestational diabetes in pregnancy237,238 
 Pregnancy in older age is associated with a higher risk of gestational hypertension239 
 Risk of eclampsia increases in young (<20) and older (≥35) mothers240 
 Risk of placental abruption increases in in young (<20) and older (≥35) mothers241 
Income 
 Women of a lower socioeconomic status are at a higher risk of developing eclampsia240 
Alcohol 
 Use of alcohol in pregnancy increases risk of placental abruption in pregnancy241 
Substance Use 
 Substance abuse is associated with placental abruption242 
Obesity 
 Maternal obesity increases risk of venous thromboembolism243 
 Pre-pregnancy obesity is associated with risk of gestational diabetes in pregnancy237,244 
 Pre-pregnancy obesity was associated with the development of gestational hypertension238,239,244,245 
 Pre-pregnancy obesity is associated with preeclampsia and eclampsia in pregnancy 240,244–248 
Diabetes 
 Women with a history of diabetes were at risk of developing gestational diabetes in pregnancy237 
 Women with type 1 diabetes were at a higher risk of developing preeclampsia245 
 Maternal diabetes increases risk of placental abruption in pregnancy241 
Parity 
 Women with no previous births were at a higher risk of developing gestational hypertension in pregnancy239 
 Women with no previous births had a higher than average risk of developing preeclampsia and eclampsia 240,246,247,249 
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 Giving birth to 3 or more children increases risk of placental abruption in pregnancy241 
History of preeclampsia 
 Women who had a preeclampsia diagnosis in a previous pregnancy were at an increased risk of a subsequent one247 
 History of preeclampsia increases risk of a placental abruption in pregnancy241 
Hypertension 
 Hypertension diagnosed prior to pregnancy is associated with a high risk of preeclampsia/eclampsia in women248 
 Hypertension increases risk of placental abruption in pregnant women241 
Placental Previa 
 Placental previa in pregnancy increases the risk of placental abruption241 
Previous history of gestational diabetes 
  Gestational diabetes in prior pregnancies is a risk factor for the development of gestational diabetes238 
Labour and 
Delivery 
Outcomes  
Age 
 Increasing maternal age is associated with increased risks of a cesarean delivery250 
 Pregnancy in age over 35 increases the risk of a forceps/ventouse delivery251 
 Increasing age is associated with an episiotomy in delivery252 
Income 
 Women in Canada’s lowest-income neighbourhoods are significantly more likely to have caesarean 
sections than those in the highest-income areas253 
Parity 
 Decreasing parity is associated with an increased risk of cesarean section delivery250 
 A woman who is giving birth to the first child is at a higher risk of experiencing perineal trauma254–256 
Obesity 
 Obesity is significantly associated with an increased cesarean delivery rate244,257 
Diabetes 
 Pre-pregnancy diagnosis of diabetes is associated with a cesarean delivery250  
Epidural Use 
 Use of epidural in pregnancy has been associated with cesarean delivery250 
 Epidural use is a strong risk factors for forceps/ventouse delivery in women251 
Psychiatric 
Readmission 
Age 
 Younger age is associated with increased risk of readmission258 
Income 
 Low income is associated with a higher risk of hospital readmission258 
Previous Hospitalization 
 A previous hospitalization or number of previous psychiatric hospitalizations is associated with an increased risk of 
readmission258–260 
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Suicide 
 Suicide ideation is associated with risk of readmission261 
Recurrence 
 Experiencing recurrence episodes during pregnancy may be severe enough to warrant readmission  
Alcohol 
 History of alcohol abuse has been shown to increase risk of psychiatric readmission260 
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Appendix G. Unadjusted and adjusted risk ratios for maternal outcomes 
 Unadjusted Estimates 
RR (95% CI) 
Adjusted Estimates 
RR (95% CI) 
Treatment: No drug Reference Reference 
Antipsychotic Only 1.12 (0.82-1.54) 1.04 (0.80-1.35) 
Antidepressant Only 0.92 (0.54-1.56) 0.94 (0.60-1.49) 
Antipsychotic and Antidepressant Polytherapy 2.00 (1.19-3.38)* 1.73 (0.99-3.01) 
Age Groups: 13-19 0.74 (0.44-1.23) 0.74 (0.48-1.33) 
20-29 Reference Reference 
30-39 1.34 (1.08-1.66)* 1.48 (1.19-1.83)* 
40-50 1.54 (0.93-2.56) 1.93 (1.11-3.36)* 
Number of Previous Births: 0 Reference Reference 
1 0.88 (0.69-1.14) 0.69 (0.54-0.88)* 
2+ 1.03 (0.81-1.32) 0.78 (0.61-1.00) 
Income: 1- Lowest neighbourhood income quintile Reference Reference 
2  1.13 (0.86-1.49) 1.08 (0.84-1.39) 
3 1.70 (1.29-2.25)* 1.42 (1.09-1.86)* 
4 1.23 (0.87-1.73) 1.22 (0.89-1.67) 
5 1.15 (0.77-1.74) 1.22 (0.89 -1.30) 
Obesity 1.59 (1.24-2.04)* 1.52 (1.19-1.95)* 
History of Gestational Diabetes 1.76 (1.16-2.66)* 1.46 (0.96-2.23) 
Pre-existing Diabetes 0.58 (0.25-1.38) 0.49 (0.22-1.13) 
Pre-existing Hypertension 1.82 (1.07-3.07)* 0.83 (0.53-1.30) 
Previous Pregnancy with Preeclampsia 2.35 (1.08-5.12)* 3.39 (1.44-8.00)* 
Prior Alcohol Related Disorders 1.03 (0.81-1.31) 0.95 (0.75-1.20) 
Prior Substance Related Disorders 0.89 (0.73-1.10) 0.85 (0.70-1.04) 
Placental Previa 14.49 (12.72-16.51)* 14.41 (12.26-16.93)* 
* p< 0.05 
CI=confidence interval 
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Appendix H. Unadjusted and adjusted risk ratios for neonatal outcomes 
 Unadjusted Estimates 
RR (95% CI) 
Adjusted Estimates 
RR (95% CI) 
Treatment: No drug Reference Reference 
Antipsychotic Only 1.04 (0.92-1.17) 1.02 (0.92-1.14) 
Antidepressant Only 1.02 (0.85-1.22) 0.98 (0.83-1.16) 
Antipsychotic and Antidepressant Polytherapy 1.17 (0.92-1.49) 1.11 (0.89-1.39) 
Age Groups: 13-19 0.80 (0.67-0.95)* 0.85 (0.72-1.00) 
20-29 Reference Reference 
30-39 0.99 (0.92-1.08) 0.99 (0.91-1.08) 
40-50 1.03 (0.84-1.27) 1.05 (0.85-1.28) 
Number of Previous Births: 0 Reference Reference 
1 0.97 (0.88-1.06) 0.93 (0.85-1.02) 
2+ 0.99 (0.90-1.08) 0.96 (0.87-1.05) 
Income: 1 - Lowest neighbourhood income quintile Reference Reference 
2 0.96 (0.87-1.06) 0.98 (0.89-1.07) 
3 0.97 (0.87-1.08) 0.98 (0.88-1.10) 
4 0.97 (0.86-1.10) 0.96 (0.86-1.08) 
5 1.00 (0.87-1.15) 1.04 (0.90-1.19) 
Previous Delivery with Preterm Birth  2.61 (2.49-2.73)* 2.65 (2.51-2.78)* 
Obesity 1.05 (0.94-1.16) 0.99 (0.89-1.10) 
Prior Substance Related Disorders 1.17 (1.08-1.26)* 1.14 (1.06-1.22)* 
Rapid Repeat Pregnancy 0.98 (0.69-1.38) 0.88 (0.64-1.21) 
Placental Previa 1.38 (1.18-1.60)* 1.05 (0.91-1.21) 
Pre-existing Diabetes 1.18 (0.97-1.44) 0.89 (0.73-1.08) 
* p< 0.05 
CI=confidence interval 
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Appendix I. Unadjusted and adjusted risk ratios for fetal outcomes 
 Unadjusted Estimates 
RR (95% CI) 
Adjusted Estimates 
RR (95% CI) 
Treatment: No drug Reference Reference 
Antipsychotic Only 1.13 (0.82-1.57) 1.11 (0.80-1.54) 
Antidepressant Only 1.35 (0.86-2.12) 1.33 (0.85-2.09) 
Antipsychotic and Antidepressant Polytherapy 1.24 (0.61-2.53) 1.16 (0.57-2.37) 
Age Groups: 13-19 0.80 (0.50-1.27) 0.68 (0.41-1.13) 
20-29 Reference Reference 
30-39 0.99 (0.79-1.24) 1.03 (0.80-1.31) 
40-50 1.00 (0.54-1.82) 0.99 (0.50-1.94) 
Number of Previous Births: 0 Reference Reference 
1 0.90 (0.70-1.14) 0.86 (0.66-1.11) 
2+ 0.70 (0.53-0.92)* 0.59 (0.43-0.80)* 
Income: 1 - Lowest neighbourhood income quintile Reference Reference 
2 1.02 (0.78-1.33) 1.05 (0.80-1.39) 
3 0.86 (0.62-1.21) 0.80 (0.56-1.15) 
4 1.05 (0.74-1.48) 1.04 (0.72-1.50) 
5 1.17 (0.80-1.71) 1.05 (0.69-1.59) 
Obesity 0.95 (0.70-1.29) 0.85 (0.61-1.19) 
Alcohol Related Disorders 1.17 (0.92-1.48) 1.15 (0.88-1.51) 
Substance Related Disorders 1.08 (0.88-1.33) 1.04 (0.81-1.32) 
Pre-existing Diabetes 1.59 (0.95-2.66) 1.65 (0.94-2.91) 
* p< 0.05 
CI=confidence interval 
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Appendix J. Unadjusted and adjusted risk ratios for labour and delivery outcomes 
 Unadjusted Estimates 
RR (95% CI) 
Adjusted Estimates 
RR (95% CI) 
Treatment: No drug Reference Reference 
Antipsychotic Only 1.03 (0.94-1.12) 1.02 (0.93-1.11) 
Antidepressant Only 1.04 (0.92-1.19) 1.03 (0.91-1.17) 
Antipsychotic and Antidepressant Polytherapy 1.11 (0.93-1.33) 1.08 (0.91-1.30) 
Age Groups: 13-19 0.91 (0.80-1.03) 0.83 (0.73-0.95)* 
20-29 Reference Reference 
30-39 1.12 (1.06-1.19)* 1.15 (1.09-1.23)* 
40-50 1.32 (1.18-1.47)* 1.36 (1.21-1.53)* 
Number of Previous Births: 0 Reference Reference 
1 0.87 (0.82-0.93)* 0.83 (0.77-0.89)* 
2+ 0.81 (0.76-0.87)* 0.76 (0.70-0.82)* 
Income: 1 - Lowest neighbourhood income quintile Reference Reference 
2 1.00 (0.93-1.07) 1.00 (0.93-1.07) 
3 1.03 (0.95-1.12) 1.03 (0.94-1.12) 
4 1.02 (0.93-1.12) 1.00 (0.91-1.10) 
5 1.02 (0.92-1.14) 1.01 (0.91-1.13) 
Obesity  1.16 (1.08-1.24)* 1.12 (1.04-1.21)* 
Pre-existing Diabetes 1.25 (1.11-1.41)* 1.18 (1.03-1.34)* 
Epidural Use 1.11 (0.90-1.36) 1.13 (0.91-1.40) 
* p< 0.05 
CI=confidence interval 
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Appendix K. Unadjusted and adjusted risk ratios psychiatric readmission outcomes 
 Unadjusted Estimates 
RR (95% CI) 
Adjusted Estimates 
RR (95% CI) 
Treatment: No drug Reference Reference  
Antipsychotic Only 0.75 (0.39-1.43) 0.79 (0.40-1.58) 
Antidepressant Only 1.13 (0.50-2.55) 1.22 (0.53-2.85) 
Antipsychotic and Antidepressant Polytherapy 1.79 (0.68-4.72) 1.24 (0.39-4.00) 
Age Groups: 13-19 0.49 (0.18-1.33) 0.42 (0.10-1.68) 
20-29 Reference Reference 
30-39 1.34 (0.94-1.90) 1.51 (0.99-2.31) 
40-50 0.55 (0.14-2.21) 0.42 (0.06-2.95) 
Income: 1 - Lowest neighbourhood income quintile Reference Reference 
2 0.80 (0.50-1.26) 0.71 (0.41-1.22) 
3 0.82 (0.48-1.42) 1.01 (0.55-1.85) 
4 1.08 (0.63-1.85) 0.64 (0.30-1.38) 
5 0.96 (0.50-1.86) 0.83 (0.36-1.90) 
History of Suicide Attempt 1.50 (0.92-2.44) 0.90 (0.45-1.79) 
Prior Alcohol Related Disorders 1.41 (0.97-2.05) 0.88 (0.53-1.47) 
Recurrence of Mood Episode in Current Pregnancy 3.41 (2.43-4.80)* 3.64 (2.36-5.63)* 
Number of BD Hospitalizations Prior to Pregnancy 1.13 (1.09-1.16)* 1.09 (1.05-1.12)* 
Psychiatric Emergency Department Visits Prior to 
Pregnancy 
1.09 (1.07-1.12)* 1.06 (1.02-1.10)* 
* p< 0.05 
CI=confidence interval 
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